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 1 
1.0 The Chemistry of NAD(P) and its 
physiological roles 
 
Nicotinamide adenine dinucleotide (NAD) and its phosphorylated counterpart 
(NADP) are ubiquitous dinucleotides, since they consist of two nucleotides joined 
through their phosphate groups. In particular, one nucleotide contains an adenine 
base and the other nicotinamide, namely adenosine monophosphate (AMP) and 
nicotinamide mononucleotide (NMN), respectively. Because of the presence of a 
pyridine ring on the NMN moiety, due to the fact that nicotinamide is a derivative 
of pyridine, NAD and NADP are also referred as pyridine nucleotides (Figure 1A). 
The presence of an additional phosphate group at the 2’ position on the ribose of 
the AMP moiety represents the chemical difference between NAD and NADP. 
Both these molecules exist in the form of a pair comprising an oxidized and a 
reduced form, NAD+/NADH and NADP+/NADPH, and are termed redox couples. 
It is usual to refer to the NAD+/NADH and NADP+/NADPH couples as NAD and 
NADP, respectively; all these species are collectively indicated as NAD(P). The 
chemical difference between the two species in each redox couple depends on the 
transfer of a hydride ion, consisting of two electrons and a proton, at the level of 
the nicotinamide ring constituting the reactive portion of NAD(P)+ (Figure 1B). 
This transfer is driven by numerous hydride transfer enzymes or oxidoreductases, 
which interconvert either NAD+ and NADH or NADP+ and NADPH to reduce or 
oxidize small-molecule metabolites in the biological systems. On the basis of their 
capacity to support the activity of enzymes catalysing oxidation-reduction 
reactions, as hydride acceptors and donors, NAD and NADP are defined 
coenzymes. 
  




Figure 1.A. Chemical structure of NAD+. Instead of a hydrogen atom, NADP+ has a phosphate 
group at the 2’ position on the ribose of its AMP moiety. B. Bi-directional redox reaction 
between NAD+ and NADH. 
 
 
Moreover, it is now well established that pyridine nucleotides and the balance 
between their oxidized and reduced forms play a wide variety of pivotal roles in 
cellular functions as important interfaces, beyond their coenzymatic activity. These 
include maintenance of redox status, cell survival and death, ion channel 
regulation, and cell signalling under normal and pathological conditions (1). In the 
role of signal transducer, NAD(P)+ is a substrate of many enzymes and need to be 
constantly resynthesized in the cell. 
  
showed that NAMPT expression is regulated in a circa-
dian fashion (38, 39). The core clock components of the
circadian machinery regulate the recruitment of SIRT1 to
the NAMPT promoter to increase NAMPT expression.
This is followed by NAD! biosynthesis, which in turn will
activate sirtuins as well as other NAD!-dependent en-
zymes. In a negative feedback loop, SIRT1 will repress the
clock components and thereby NAMPT expression (38,
39). It is suggested that through this mechanism, NAMPT
(38, 39) and SIRT1 (40, 41) may play a crucial role in the
circadian regulation of metabolism. After the NAMPT
reaction, NMN is converted to NAD! by NMNAT,
which is able to condense the adenylyl moiety to both
NAMN and NMN (16 –18, 42).
A third NAD! salvage pathway, which was long
known as the only NAD! biosynthesis pathway in certain
bacteria, is comprised of the phosphorylation of NR to
NMN by NR kinase (NRK), after which one of the
NMNAT enzymes catalyzes the formation of NAD!. Re-
cently, this pathway was shown to be highly conserved
and also active in yeast and humans, for which two NRK
enzymes have been described (43). The NRK1 isoform
is ubiquitously expressed, whereas NRK2 localization
seems to be restricted to heart, brain, and muscle (44).
The discovery of R as a nutrient in cow milk (43) poses
an interesting opportunity for therapeutic intervention
in NAD!-dependent metabolism, as will be discussed in
Section IX.
C. Substrate preference for NAD! biosynthesis
The existence of four pathways for NAD! biosynthesis
originating from four independent precursors raises ques-
tions regarding the fluxes of metabolites. As mentioned in
Sections II.A and II.B, some of the enzymes involved in
NAD! biosynthesis are strictly localized to a limited
number of organs. Also, some enzymes, for instance
NMNAT1-3, clearly show different subcellular localiza-
tion. To date there is no consensus with respect to the
question of the preferred substrate of NAD!. Feeding of
rats with tryptophan, NA, or NAM showed that the first
resulted in the highest NAD! concentration in liver, sug-
gesting that this is the preferred substrate at least in this
organ (45). These results were confirmed in isolated hepa-
tocytes, showing thatNAandNAMarenormally takenup
from the medium but are not used for NAD! biosynthesis
















































































FIG. 2. Mammalian NAD! salvage pathway. NAD! is synthesized in the NAD! salvage pathway from its precursors NA, NAM, or NR. The initial
step in NAD! synthesis from NA, the so-called Preiss-Handler pathway, is catalyzed by NAPT and results in the formation of NAMN, which can also
be derived from de novo NAD! biosynthesis. In an identical reaction, but catalyzed by a different enzyme, NAM is converted by NAMPT forming
NMN, which is also the product of phosphorylation of NR by NRK. The subsequent conversion of both NAMN and NMN is catalyzed by the same
enzyme, i.e., NMNAT. In the case of NAMN, this reaction is followed by amidation, finally producing NAD!. NADS, NAD synthase.
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FIG. 2. Mammalian NAD! salvage pathway. NAD! is synthesized in the NAD! salvage pathway from its precursors NA, NAM, or NR. The initial
step in NAD! synthesis from NA, the so-called Preiss-Handler pathway, is catalyzed by NAPT and results in the formation of NAMN, which can also
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NMN, which is also the product of phosphorylation of NR by NRK. The subsequent conversion of both NAMN and NMN is catalyzed by the same
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enzymes that cleave NAD+ to produce Nam and an
ADP-ribosyl product. Although, historically, these
enzymes have been called NAD+ glycohydrolases, NAD+-
dependent ADP-ribosyl transferase is a more precise term
[5]. However, to avoid confusion with dedicated protein
mono(ADP-ribosyl) transferases, we refer to the enzymes
historically termed NAD+ glycohydrolases as NAD+ con-
sumers. As depicted in Figure 3, the three classes of NAD+
consumers are (i) ADP-ribose transferases or poly(ADP-
ribose) polymerases, (ii) cADP-ribose synthases and (iii)
sirtuins (type III protein lysine deacetylases).
The substantial flux through NAD+-consuming
pathways explains why people require niacin supple-
mentation when tryptophan is limiting. If NAD+ were
only a coenzyme (i.e. not consumed but merely inter-
converted between oxidized and reduced forms by
hydride transfer), the nutritional requirement to support
ongoing synthesis in excess of that provided by the de
novo pathway would be difficult to explain. Thus, we now
believe that either dietary niacins or NR in conjunction
with niacin and/or NR-salvage are required to maintain
NAD+ in cells that are undergoing rapid NAD+ break-
down (Figure 2).
ARTs and PARPs
ADP-ribose transferases (ARTs) and the more numerous,
poly(ADP-ribose) polymerases (PARPs) consume NAD+ to
create an ADP-ribosyl protein modification and/or to form
the ADP-ribose polymer, PAR (Figure 3). In a comprehen-
sive review of the function of ARTs and PARPs, de Murcia
describes numerous conditions that induce this type of
NAD+ catabolism and the consequent ADP-ribose reaction
products in DNA-damage responses, epigenetic modifica-
tion, transcription, chromosome segregation and pro-
grammed cell death [6]. Because of the roles of PARPs
in cell death, there are substantial pre-clinical and inves-
tigative efforts to inhibit PARP to protect against cardiac,
inflammatory and neurodegenerative conditions [7]. How-
ever, because PARP has complex roles in cell survival and
repair signaling in addition to mediating cell death, it
might be difficult to develop neuroprotective strategies
that involve chronic inhibition of this essential enzyme
[7]. Moreover, much of the benefit associated with inhibi-
tion of PARP might be related to protecting cellular
NAD+, such that NAD+-boosting therapies targeted to
tissues in which PARP is activated might be safer and
as effective.
cADP-ribose synthases
cADP-ribose synthases are a pair of ecto-enzymes also
known as the lymphocyte antigens CD38 andCD157, which
produce and hydrolyze the Ca2+-mobilizing second-messen-
ger cADP-ribose from NAD+ [8–10] (Figure 3). CD38 cata-
lyzes a base exchange between NADP+ and Na to form Na
adenine dinucleotide phosphate (NaADP) [11], which is also
a hydrolytic substrate [12]. All the products of CD38 (cADP-
ribose, ADP-ribose and NaADP) have distinctive roles in
Ca2+ mobilization.
Figure 1. NAD+ as a coenzyme for reversible hydride transfer. In a typical NAD+-dependent oxidation, an alcohol is converted to the corresponding aldehyde with the
production of NADH plus a proton. In the NADH-dependent direction, an aldehyde is reduced to an alcohol, which regenerates NAD+.
Box 1. History of the NAD+ coenzyme
In the early 20th century, Arthur Harden and co-workers reconstituted
cell-free glucose fermentation with two fractions, one termed
‘zymase’ that was heat-labile and retained by dialysis, and one
termed ‘cozymase’ that was heat-stable and passed through dialysis.
Zymase was not a purified enzyme but a protein fraction that
contained glycolytic enzymes. The cozymase fraction contained
ATP, Mg2+ and the NAD+ coenzyme, the structure of which was
determined by Otto Warburg. In glucose fermentation, NAD+ func-
tions as the hydride acceptor in the step catalyzed by glyceraldehyde-
3-phosphate dehydrogenase, producing NADH and diphosphoglyce-
rate. Similarly, NADH functions as the hydride donor for alcohol
dehydrogenase, which is required for the reduction of acetaldehyde
to ethanol, regenerating NAD+. Numerous hydride transfer enzymes
or oxidoreductases interconvert either NAD+ and NADH or NADP+ and
NADPH to reduce or oxidize small-molecule metabolites (see Figure 1
in the main text).
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 3 
1.0.1 NAD(P)-the coenzyme 
 
Since the beginning of the last century, seminal discoveries have identified pyridine 
nucleotides as the major redox carriers in all organisms. Indeed, it is beyond doubt 
that NAD(P) holds a key position in cellular metabolism and energy production due 
to its coenzymatic activity. The function of NAD as coenzyme was firstly 
discovered by Otto Warburg, in 1936. On the basis of his work on alcoholic 
fermentation, he discovered the capability of NAD, at that time known as “von 
Euler’s cozymase”, to transfer hydrogen from one molecule to another. We have to 
credit Warburg also with the discovery of NADP, the “cozymase II”, as another 
coenzyme with similar properties (2, 3). In the cellular metabolism, the 
NAD+/NADH couple primarily drives oxidation reactions (catabolic reactions), 
while the NADP+/NADPH couple drives reductive reactions (anabolic reactions). 
Fatty acid β-oxidation and biosynthesis are an example of metabolic pathways 
where NAD+/NADH and NADP+/NADPH are involved as coenzymes, 
respectively. To understand the reason why the two redox couples are generally 
implicated in those distinct branches of cellular metabolism, it has to be considered 
their redox potentials (4). The intrinsic tendency of a chemical species to acquire 
electrons is expressed by its reductive potential, also known as redox potential, that 
is measured in volt (V); the more positive the redox potential is, greater the 
electron affinity of the considered species will be. Both in the cytosol and the 
mitochondrial matrix, the NADP redox potential is higher than the NAD one 
(Figure 2); that means that the ratio NADPH/NADP+ is much greater than 
NADH/NAD+ ratio in the mitochondrial matrix. One process maintaining this 
disequilibrium is the mitochondrial proton motive force-dependent 
transhydrogenase (5). Moreover, it has long been recognized that the reductive 
potential of NAD is much higher than that in the cytosol, corresponding to a 40-
fold difference in the NAD+/NADH ratio in the two compartments (Figure 2). 




Figure 2. Redox potentials of the mitochondrial and cytosolic NAD(H) and NADP(H) systems 
in the liver. c, cytosolic; m, mitochondrial. (modified from ref. 4). 
 
 
The redox state of NAD and NADP, their different distribution in distinct cell types 
and tissues, together with the well-established presence of intracellular binding 
proteins modulating the free concentration of NAD(P) (4), all these factors 
contribute in determining the redox state of the cell, that represents itself an 
important regulatory mechanism. Indeed, the expression of several genes is linked 
to the redox state of pyridine nucleotides via NAD+/NADH-binding proteins that 
act as redox sensors (6). For example, transcriptional activity can be reciprocally 
regulated by direct binding of either NADH or NAD+ to transcriptional co-
repressor C-terminal binding protein (7). Pyridine nucleotides have been shown to 
serve as electron carriers to synthesize adenosine triphosphate (ATP) in 
mitochondria via the electron transport chain (ETC) and oxidative phosphorylation. 
The participation of NAD(P) in electron transfer reactions, does not result in a net 
consumption of the nucleotides. Consequently, except for cell divisions, the 
biosynthesis pathway, NAM is thought to be preferred
over NA as the main precursor for NAD! biosynthesis.
This is illustrated by the fact that mice receiving an ip
injection of NA only have a transient increase in NAD!
concentration accompanied by a high excretion rate of
nicotinuric acid in urine, accounting for 36% of the ad-
ministered NA. In contrast, NAM injection results in a
more stable increase in NAD! levels, with very limited
nicotinuric acid excretion (25). Whether or not NAM is
directly transported into the cell or is metabolized extra-
cellularly remains unknown. Because both intra- and ex-
tracellular NAMPT have been reported, as well as circu-
lating NMN (36), it seems plausible that both pathways
contribute to NAD! biosynthesis. In addition, the lack of
NAMPT in some tissues suggests that these either use
other substrates for NAD! biosynthesis or convert NAM
in the circulation. Recently, an NR transporter (Nrt1) has
been described in yeast (47). Nrt1 belongs to the family of
sodium-coupled transporters and was essential for opti-
mal NAD! synthesis and for growth of yeast on NR.
NAD! synthesis from NA and NAM was not affected by
deletion of Nrt1 (47). The human ortholog of Nrt1 is yet
unknown, although some transporters have been identi-
fied that are capable of transporting the NR analogs ben-
zamide riboside and tiazofurin (48). Despite the signifi-
cant advances in the field of NAD! metabolism, especially
since sirtuins have come to center stage, it remains to be
established how the various pathways interact and which
precursors are preferentially used in vivo. The elucidation
of the transport pathways could advance this field of re-
search and clarify the relevant pathways for NAD!
synthesis.
III. Role of NAD! in Cellular Redox State
Pioneering work by Warburg and co-workers in the 1930s
has led to the identification of the NAM dinucleotides
NAD(H) and NADP(H) (49, 50). Indeed, NADP! was
discovered as the coenzyme of the glucose-6-phosphate
dehydrogenase reaction, whereas NAD! turned out to be
the obligatory cofactor of fermentation. Later studies re-
vealed that NAD and NADP play an indispensable role in
cellular oxidation/reduction reactions, with the NAD!/
NADH couple primarily driving oxidation reactions and
the NADP!/NADPH couple driving reductive reactions.
The underlying basis for this remarkable difference be-
tween the NAD!/NADH- and NADP!/NADPH-redox
couples has to do with the fact that the redox potentials of
the two redox couples are widely different, with the
NADP(H)-redox couple being much more reduced than
the NAD(H)-redox couple (Fig. 3). The mitochondrial en-
zyme energy-linked transhydrogenase is responsible for
this phenomenon as will be discussed in Section III.B.
The contents of the NAM nucleotides in distinct cell
types and tissues iffer markedly, espec ally if NADP p us
NADPH is concerned. For instance, in rat liver tota NAD,
i.e., NAD! plus NADH, amounts to some 800 nmoles/g
wet weight, whereas total NADP amounts to about 420
nmoles/g wet weight. For skeletal muscle, however, these
values are 590 and 30 nmoles/g wet weight, respectively.
Apart from the differences in absolute levels, there is also
the fact that NAD and NADP are heavily compartmen-
talized, with mitochondria containing high levels of
NAD(H)andNADP(H).This explainswhy thepercentage
of NAD and NADP present in mitochondria, compared
with the total amount of tissue, is higher in heart tissue
than in liver tissue, especially if NAD is concerned (35 vs.
20%; Ref. 51), considering that mitochondria are more
abundant in heart compared with liver.
A. Cellular NAD(H) and NADP(H): binding to proteins,
and the metabolite indicator method
It has long been established that NAD(H) and
NADP(H) are predominantly bound to intracellular pro-
teins and that the free concentrations of NAD!, NADH,
NADP!, and NADPH are much lower than the total con-
centrations as determined in protein-free tissue extracts
obtained by acidification (NAD! and NADP!) and alka-
linization (NADH and NADPH). The existence of these
binding sites, which bind NADH and NADPH more av-
idly than NAD! (and NADP!) complicates the determi-
nation of the true redox state of the NAD(H)- and
NADP(H)-redox couples within any tissue or cell.
To circumvent this problem, the so-called metabolite
indicator method has been conceived (51). This elegant
method is based on the notion that a particular NAD!/
NADH-ratio may be calculated from the concentrations
of a certain oxidized substrate and reduced substrate, par-
ticipating in a NAD(H)-linked dehydrogenase reaction,
provided that the selected dehydrogenase catalyzes a near-











FIG. 3. Redox potentials of the mitochondrial and cytosolic NAD(H)
and NADP(H) systems in the liver. c, Cytosolic; m, mitochondrial.
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constant requirement for pyridine nucleotide resynthesis does not arise from their 




1.0.2 NAD(P)+- the substrate  
 
Nowadays, it is well assessed that pyridine nucleotides, besides their vital functions 
as electron carriers, play important roles as mediators in a plethora of fundamental 
cellular processes. Since many years, it has been discovered an astonishing range of 
enzymatic activities where NAD(P)+ is not involved as a coenzyme but rather as a 
substrate. These NAD(P)+-consuming enzymes get the energy to proceed in the 
catalysis of their reactions by the cleavage of the N-glycosidic bond between the 
nicotinamide ring and the ribose of the NMN moiety of NAD(P)+. Indeed, 
nicotinamide (Nam) and ADP-ribose (ADPr) are the common products of all these 
reactions; Nam can be recycled entering the NAD+ salvage pathway while the 
ADPr is transferred to an acceptor molecule or can undergo a cyclization (see 
below) (Figure 3). NAD(P)+-consuming enzymes drive essentially post-
translational protein modification and messenger molecule synthesis reactions that 
are involved in important functions in metabolism, signalling transduction, cell 
survival and death as well as in gene expression regulation and aging. It is 
important to note that all the conversions require the oxidized form of NAD(P)+. 
The reduced form is not a substrate for these signalling reactions (8). Three protein 
families that consume NAD(P)+ in signalling reactions have been characterized on 
a molecular level: ADP-ribosyltransferases (ARTs and PARPs), Sirtuins (SIRTs), 
and NAD+ glycohydrolases (NADases) (6). NAD+-dependent ADP-ribosylation is 
an important post-translational reversible protein modification that regulates 
diverse biological processes including DNA-repair, transcriptional regulation, 
telomere dynamics, energy metabolism and apoptosis (10, 11).  




Figure 3. Consumption of NAD+ driven by NAD(P)+ dependent enzymes. All the reactions 
catalysed by NAD+-consuming proteins use NAD(P)+ as a donor of ADPr, while generating 
nicotinamide (Nam) as a side product. Nicotinamide has the product inhibition effect on the 
enzymatic activities of most of the NAD+-consuming proteins, probably by competing for the 
NAD+ binding pocket (modified from ref .9). 
 
 
ADP-ribosylation enzymes (ARTs) can be distinguished in mono- and poly-ADP-
ribosyltransferases and catalyse, respectively, the transfer of one or more ADP-
ribose moieties from NAD+ onto specific aminoacid side chains in target protein 
under release of nicotinamide (Figure 4). In mammals, the ART family is the 
largest and, perhaps, most versatile among the NAD+-converting protein families 
(12), and that has generated some confusion about a common shared nomenclature 
(13). 
  




Figure 4. ADP-ribosylation reaction. Mono-ADP-ribosyltransferases catalyse the transfer of one 
unit of NAD+; Poly-ADP-ribosyltransferases catalyse an adduct elongation, giving rise to polymers 
of up to about 200-ADP-ribosyl units. Arrows indicate the site of hydrolysis catalysed by PARG 
(modified from ref. 11). 
 
 
Sequence and structure homology searches have identified 22 human genes 
encoding proteins with ADP-ribosylation activity that have been grouped into three 
major families: the extracellular membrane-associated ADP-ribosyltransferases 
(ecto-ARTs), a single member family of NAD+-dependent tRNA 2’-
phosphotransferases and the poly-ADP-ribose polymerases (PARPs) (13). 
Apart from the covalent modification of acceptor
proteins, poly(ADP-ribose) has also been shown to
interact noncovalently, yet specifically, with a wide
range of proteins [3]. This interaction is mediated
through a sequence motif displaying a conserved pat-
tern, and it is interesting to note that DNA damage
checkpoint proteins such as p53 and p21 possess such
poly(ADP–ribose) interact on domains. DNA methyl-
transferase-1 (DNMT1) is also able to bind long and
branched ADP-ribose polymers in a noncovalent fash-
ion, which leads to inhibition of DNMT1 activity [4].
Taken together, poly(ADP-ribose) can also affect the
function of proteins that are not direct modification
targets.
Enzymes involved in poly(ADP-ribose)
metabolism
PARP-1
The prototypic enzyme of the PARP family is poly
(ADP-ribose) polymerase-1 (PARP-1; EC 2.4.2.30;
Table 1). Its discovery was made four decades ago by
Chambon, Weill and Mandel [5] and marked the birth
of a most interesting and intriguing field originally
occupied by biochemists, but later on also attracting
radiobiologists, toxicologists, geneticists, molecular
biologists, pharmacologists, cell biologists and experts

































































































































Fig. 1. Poly(ADP-ribose) structure.
Poly(ADP-ribose) polymerases (PARPs)
cleave the glycosidic bond of NAD+
between nicotinamide and ribose followed
by the covalent modification of mainly glu-
tamate residues of acceptor proteins with
an ADP-ribosyl unit. PARPs also catalyse
an adduct elongation, giving rise to linear
polymers with chain lengths of up to about
200 ADP-ribosyl units, characterized by
their unique ribose (1¢¢fi2¢) ribose phos-
phate-phosphate backbone. At least some
of the PARP family members also catalyse
a branching reaction by creating ribose
(1¢¢¢fi2¢¢) ribose linkages. The sites of
hydrolysis catalysed by poly(ADP-ribose)
glycohydrolase (PARG), the major poly(ADP-
ribose)-degrading enzyme, are indicated
by arrows.
A. Bürkle Poly(ADP-ribosyl)ation
FEBS Journal 272 (2005) 4576–4589 ª 2005 FEBS 4577
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Surprisingly, all identified ecto-ARTs are mono-ADP-ribosyltransferases (2) and 
their activity in the extracellular compartment provides a complex regulatory 
mechanism for cell communication (13). Mono-ADP-ribosylation (MARylation) 
was originally identified as the catalityc activity of several bacterial toxins such as 
diphtheria, cholera and pertussis toxins, and its physiological roles are related to 
immune response and inflammation, transcription regulation, cell adhesion, signal 
and energy metabolism (14). Many functions of Poly-ADP-ribosylation 
(PARylation) may be explained considering the multiple roles played by PARP-1, 
the most studied human poly-ADP-ribosyltransferase, now considered a 
moonlighting protein that serves the cells both in peace (resting condition) and in 
war (DNA damage) (15). After the discovery of PARP-1 in the early 1960s, many 
other enzymes with poly ADP-ribosyltransferase activity had been discovered, 
highlighting a huge number of conditions inducing ADP-ribose polymer (PAR) 
formation (11). Both mono- and poly- ADP-ribosylation are dynamic processes 
because of the presence of other enzymes, ADP-ribosyl hydrolases (ARHs) and 
Poly-ADP-ribose glycohydrolases (PARGs), which remove mono-ADP ribose 
from the target and hydrolyse the O-glycosidic ribose-ribose 1-2’ bonds within 
PAR, respectively (16). Mono-ADP-ribosyltransferase activity was also detected in 
some sirtuins such as human mitochondrial SIRT4 and nuclear SIRT6 (17). 
Sirtuins are a family of evolutionally conserved class III histone deacylases that 
consume one molecule of NAD+ during each deacylation cicle (18). Even though 
sirtuins have been recognised mostly as deacetylases, recent studies have shown 
that Sirt5 is endowed of demalonylase and desuccinylase activities (19). 
Chemically, deacylation primarily occurs on N-ε-lysine residues and tipically 
regulates protein function (17). For example, sirtuin catalysed NAD+-consuming 
deacetylation takes place on an acetyl-lysine and results in the production of 
deacetylated lysine, nicotinamide and 2’-O-acetyl-ADP-ribose (OAADPr) (Figure 
5). 
  




Figure 5. Schematic representation of a deacetylation reaction catalysed by sirtuins (modified 
from ref. 20). 
 
 
In particular, OAADPr undergoes a non-enzymatic transesterification reaction and 
exists in solution as a mixture of 2’ and 3’ OAADPr (20). Moreover, OAADPr has 
been implicated as a signalling molecule and it can also be the substrate of 
macrodomain family enzymes that may function in the regulation of OAADPr 
cellular levels, hydrolysing the 2 or 3-ester bond to generate ADPr and acetate as 
products (16, 21). The mammalian family of sirtuins consists of seven members, 
Sirt1-7, and the number of their reported histone and non-histone protein targets is 
continually increasing. Therefore, it is not surprising that sirtuins have important 
roles in many biological processes such as regulation of chromatin structure and 
gene expression, oxidative stress reduction, glucose homeostasis and cell survival 
(4). The versatile functions of sirtuins are supported by their diverse cellular 
location allowing cells to sense changes in energy levels in the nucleus, cytoplasm, 
and mitochondrion (18), but it is not clear whether the link between intracellular 
NAD+ levels and sirtuin activity is correlative or causal (4). Alongside its 
consumption by sirtuins and ARTs, NAD(P)+ is also a substrate for NAD 
glycohydrolases enzymes, responsible for the generation of second messengers 
associated with calcium signalling, a universal signal trasduction mechanism 
involved in a wide range of physiological functions. The two major Ca2+ 
mobilising NAD(P)+ derivatives are the cyclic ADP ribose (cADPr) and the 
Nicotinic acid Adenine dinucleotide phosphate (NAADP) and, in mammals, their 
mechanism (15). Several biochemical studies support the for-
mation of the alkylamidate intermediate. These include nico-
tinamide base-exchange reactions (16) and 18O labeling studies
that provide evidence for the direct transfer of the acetyl oxygen
to the 1!-hydroxyl of OAADPr (17, 18). Utilization of acetylly-
sine analogs further demonstrated the existence of the alkyl-
amidate intermediate. Thioacetyllysine- a d acetylazalysine-
containing peptides form stalled alkylamidate intermediates
when used as sirtuin substrates (19, 20). Upon formation of the
alkylamidate intermediate, the 2!-hydroxyl group of the NAD"
ribose is activated by a conserved active-site histidine (supple-
mental Fig. 1). The activated hydroxyl attacks the O-alkylami-
date carbon to afford a 1!,2!-cyclic intermediate (20). Recently,
the bicyclic intermediate was trapped and structurally
resolved by incubating co-crystals of SIRT5 and an H3K9
thiosuccinyl-peptide with NAD", providing direct evidence
for the proposed catalytic mechanism (21). A base-activated
water molecule then attacks the cyclic intermediate, afford-
ing deacetylated lysine and OAADPr (supplemental Fig. 1)
(10, 17).
Although deacylation is thought to be the primary function
of human sirtuins, yeast Sir2 was first implicated as having the
capability to transfer ADP-ribose from NAD" to nucleophilic
amino acids on protein substrates (22). SIRT4 and SIRT6 have
also been reported to catalyze ADP-ribosyl transfer to gluta-
mate dehydrogenase and poly(ADP-ribose) polymerase 1,
respectively (7, 23). This activity is not robust and has been
subject to debate. Detailed kinetic characterization of the ADP-
ribosyltransferase activity of a yeast and bacterial sirtuin indi-
cated that ADP-ribosylation may be a low efficiency side reac-
tion (#0.1% of the deacetylation reaction) of sirtuins due to the
usc ptibility of active site-bound ADP-ribose to nucleophilic
attack (24). Understanding the mechanistic details of sirtuin-
catalyzed reactions is an important step toward a complete
understanding of sirtuin function and in the development of
chemical tools to probe their biology.
Substrate Recognition and Acyl Group Specificity
A number of proteomics studies have greatly enhanced our
understanding of lysine acetylation as a global post-transla-
FIGURE 1. Representative structure of a human sirtuin (Protein Data Bank code 3GLR) bound to acetylated peptide and NAD!. Key locations for sirtuin
modulation are highlighted. Positive regulators of sirtuin activity are indicated in green, negative regulators are indicated in red, and regulators that can
activate or inhibit depending on the sirtuin are in yellow. Proposed activators include NAD" synthesis, Sirtris compound 11 (90) and other reported activators,
and phosphorylation of SIRT1. Inhibitors include cysteine nitrosylation, DBC1 binding SIRT1, pseudopeptidic inhibitors (95) and other small molecules,
nicotinamide, and sumoylation of SIRT1.
FIGURE 2. Substrates and products of the sirtuin-catalyzed reaction and potential fate of the product OAADPr. The unique use of NAD" as a co-substrate
distinguishes sirtuins from other deacetylase classes and provides a direct link to energy metabolism.
MINIREVIEW: Sirtuin Catalysis and Regulation
42420 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 276 • NUMBER 51 • DECEMBER 14, 2012
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formation is catalysed by a single enzyme, CD38 (and its Janus CD157). cADPr 
and NAADP are structurally and functionally distinct and thus, it is surprising that 
they can be synthesized by the same enzyme. It has been shown how the different 
reactions occur at distinct pH, with the synthesis of NAADP at acidic pH, and that 





Figure 6. Generation of second messengers NAADP and cADPr by CD38. The synthesis of 
cADPr occurs at neutral pH, whereas that one of NAADP occurs at acidic pH.  
 
 
Many structural and site-directed mutagenesis studies have elucidated the 
molecular basis of the multifunctionality of CD38. Even though sharing the same 
activity, cADPr and NAADP mobilise different intracellular Ca2+ stores by binding 
distinct targets. Indeed, cADPr binds the ryanodine receptor and mobilises the 
calcium store in the endoplasmic reticulum (ER), while NAADP mobilises the 


























































Ernst et al. Adenine dinucleotide messengers in T-lymphocytes
FIGURE 1 | Metabolism of adenine derived second messengers cADPR, NAADP, and ADPR.
ligation (10). However, NAADP is a rather short-lived second
messenger, although after a rapid decrease to control levels, a
second much smaller rise over several minutes was observed in
Jurkat T cells (11). NAADP probably delivers the first local Ca2+
signals which then act as co-agonists at IP3 receptors (IP3R) and
ryanodine receptors (RyR). IP3 is formed soon after the initial
NAADP peak (12) and releases Ca2+ via IP3R (13). Finally, cADPR
starts to increase and acts on RyR (14); likely, Ca2+ released by
NAADP and/or IP3 facilitates the action of cADPR. Continuous
Ca2+ release by these consecutively increased second messengers
results in continuously decreased luminal Ca2+ concentration in
the ER ([Ca2+]lu). Stromal interaction molecule-1 (Stim1) senses
the decreased [Ca2+]lu and activates Ca2+ entry vi orai/CRAC
channels (15–17).
In addition to this Ca2+ signaling pathway involved in T
cell activation or re-activation, high input signal strength, e.g.,
obtained by a high concentration of the cross-linking lectin
Concanavalin A, activates another different Ca2+ entry system
operated by ADPR and the transient receptor potential channel,
subtype melastatin 2 (TRPM2; Figure 2).
Following we will review hallmarks of NAADP, cADPR, and
ADPR as second messengers in T cell Ca2+ signaling.
NAADP
Upon activation of the TCR/CD3 complex, formation of NAADP
rapidly increases within 10–20 s in Jurkat T cells. Following a
subsequent decrease within the first minute, a continuously ele-
vated [NAADP] remains for 5–20 min (10). It has been proposed
that NAADP may act as an early triggering messenger, mediating
initial localized Ca2+ events which are subsequently amplified to a
global signal, e.g., by recruitment of further channels, other second
messengers like cADPR, IP3, and/or Ca2+ induced Ca2+ release
(CICR). In T-lymphocytes a bell-shaped concentration-response
curve following NAADP microinjection is observed. Compared to
other second messengers such as IP3, already low concentrations
in the nanomolar range (30–100 nM) induce Ca2+ signaling in
T-lymphocytes (18).
The mechanism and very early kinetics of receptor-mediated
formation of NAADP in vivo remains unclear and has been dis-
cussed previously [e.g., (19)]. In brief, NAADP is formed in vitro
by a base-exchange of NA in presence of nicotinic acid and
a pH of 5 [Figure 1; (20)]. Further, at pH 5, but also at pH
7.4, 20-phospho-cADPR may be converted to NAADP (21). Both
reactions are catalyzed by the membrane bound, multifunctional
enzyme CD38 and require presence of up to millimolar concen-
trations of nicotinic acid in vitro (20, 21). Furthermore, influx of
extracellular NAADP may also induce Ca2+ signals as shown in a
rat basophilic cell line (22). Interestingly, gene silencing of CD38
in Jurkat T-lymphocytes did not result in decreased NAADP levels.
Rather, in thymus and spleen of CD38 knock-out mice increased
NAADP levels were observed, thus indicating that CD38 may par-
ticularly drive degradation of NAADP (23, 24). Accordingly, in
T cells to date CD38 may be primarily understood as degrading
enzyme while its role in NAADP synthesis in vivo remains to be
elucidated. In T-lymphocytes and other CD38+ cells, NAADP is
degraded to 20-phospho-ADPR at neutral and acidic pH by CD38,
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ligation (10). However, NAADP is a rather short-lived second
messenger, although after a rapid decrease to control levels, a
second much smaller rise over several minutes was observed in
Jurkat T cells (11). NAADP probably delivers the first local Ca2+
sign ls which then act as co-agonists at IP3 receptors (IP3R) and
ryanodine receptors (RyR). IP3 is f r ed so n after the initial
NAADP pe k (12) and releases Ca2+ via IP3R (13). Finally, cADPR
starts to increase and acts on RyR (14); likely, Ca2+ released by
NAADP and/ r IP3 facilitates the action of cADPR. Continuous
Ca2+ release by these consecutively increased second messengers
results in continuously decreased luminal Ca2 concentration in
the ER ([Ca2+]lu). Stromal interaction molecule-1 (Stim1) senses
the decreased [Ca2+]lu and activates Ca2+ entry via orai/CRAC
channels (15–17).
In addition to this Ca2+ sig aling pathway involved in T
cell activation or re-activation, h gh input signal strength, e.g.,
obtained by a high concentration of the cross-linking lectin
Concanavalin A, activates another different Ca2+ entry system
operated by ADPR and the transient receptor potential channel,
subtype melastatin 2 (TRPM2; Figure 2).
Following we will review hallmarks of NAADP, cADPR, and
ADPR as second messengers in T cell Ca2+ signaling.
NAADP
Upon activation of the TCR/CD3 complex, formation of NAADP
rapidly increases within 10–20 s in Jurkat T cells. Following a
subsequent decrease within the first minute, a continuously ele-
vated [NAADP] remains for 5–20 min (10). It has been proposed
that NAADP may act as an early triggering messenger, mediating
initial localized Ca2+ events which are subsequently amplified to a
global signal, e.g., by recruitment of further channels, other second
messengers like cADPR, IP3, and/or Ca2+ induced Ca2+ release
(CICR). In T-lymphocytes a bell-shaped concentration-response
curve following NAADP microinjection is observed. Compared to
oth r second messengers such as IP3, already low concentrations
in the nanomolar range (30–100 nM) induce Ca2+ signaling in
T-lymphocytes (18).
The mechanism and very early kinetics of receptor-mediated
formation of NAADP in vivo remains unclear and has been dis-
cussed previously [e.g., (19)]. In brief, NAADP is formed in vitro
by a base-exchange of NADP in presence of nicotinic acid and
a pH of 5 [Figure 1; (20)]. Further, at pH 5, but also at pH
7.4, 20-phospho-cADPR may be converted to NAADP (21). Both
reactions are catalyzed by the membrane bound, multifunctional
enzyme CD38 and require presence of up to millimolar concen-
trations of nicotinic acid in vitro (20, 21). Furthermore, influx of
extracellular NAADP may also induce Ca2+ signals as shown in a
rat basophilic cell line (22). Interestingly, gene silencing of CD38
in Jurkat T-lymphocytes did not result in decreased NAADP levels.
Rather, in thymus and spleen of CD38 knock-out mice increased
NAADP levels were observed, thus indicating that CD38 may par-
ticularly drive degradation of NAADP (23, 24). Accordingly, in
T cells to date CD38 may be primarily understood as degrading
enzyme while its role in NAADP synthesis in vivo remains to be
elucidated. In T-lymphocytes and other CD38+ cells, NAADP is
degraded to 20-phospho-ADPR at neutral and acidic pH by CD38,
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separated, these Ca2+ stores can interact through different mechanisms that have 
been proposed (22). In mammalian cells, even OAADPr and ADPr can modulate 
calcium influx through the transient receptor potential malastatin-related channel 2 
(TRPM2), a non selective cation channel that is stimulated by oxidative and 
nitrative stress (23). By mediating the Ca2+ signalling in the cells, adenine 
dinucleotides second messengers participate in the coordination of many important 
cellular processes. For example, Ca2+ signalling is fundamental in the activation of 
the T-lymphocytes, so being essential for a functional immune response (24). All 
these NAD(P)+-consuming reactions call for a continuous replenishment of the 
pyridine nucleotides. NAD(P)+ biosynthesis can be accomplished through distinct 
pathways that notably vary in prokaryotes and eukaryotes. For the scope of this 




1.1 Biosynthesis of NAD(P)+ in humans 
 
In human cells, NAD+ biosynthesis is based on several different extracellular 
precursors (Figure 7). The catabolism of tryptophan (Trp) supports NAD+ 
generation by the formation of quinolinic acid (QA) in the kynurenine pathway and 
all reactions from Trp to NAD+ are commonly referred as de novo pathway. Other 
pathways, known as salvage pathways, initiate NAD+ biosynthesis starting from 
the vitamin precursors, namely nicotinamide (Nam), nicotinic acid (Na), 
Nicotinamide riboside (NR) and nicotinic acid riboside (NaR), or recycle NAD 
degradation products (25). Although the molecular identities of the human enzymes 
involved in NAD(P)+ synthesis have been established, information regarding their 
subcellular distribution and regulation is scarce or inconclusive (26). 
  




Figure 7. Overview of NAD+ biosynthesis in humans (26). 
 
 
1.1.1 De novo pathway  
 
Tryptophan is the de novo precursor of NAD+ in all vertebrates (3) and is taken up 
from the diet (27). In particular, tryptophan serves as a NAD+ precursor when 
degraded to quinolinic acid (QA) in the kynurenine pathway (Figure 8). The first 
rate-limiting step in de novo NAD+ biosynthesis is the conversion of tryptophan to 
N-formylkynurenine by either indoleamine 2,3, dioxygenase (IDO) or tryptophan 
2,3, dioxygenase (TDO), both catalysing the indole ring cleavage at the C2-C3 
bond, and requiring molecular oxygen. These two enzymes show distinct substrate 
specificity and are differently expressed in the various tissues and organs.  
2908 Current Topics in Medicinal Chemistry, 2013, Vol. 13, No. 23 Dölle et al. 
Fig. (1). Overview of NAD biosynthesis in humans. NAD biosynthesis initiates from different entry points. Nicotinamide phosphoribosyl-
transferase (NamPRT) and nicotinic acid phosphoribosyltransferase (NAPRT) catalyze the respective conversion of nicotinamide (Nam) and 
nicotinic acid (NA) to the intermediates nicotinamide mononucleotide (NMN) and nicoti ic acid mononucleotide (NAMN). Transformation 
of quinolinic acid (QA) by quinolinic acid phosphoribosyltransferase (QAPRT) also yields NAMN. All three reactions use phosphoribosyl 
pyrophosphate (PRPP) as phosphoribosyl donor. Nicotinamide riboside kinase (NRK) activity transforms nicotinamide riboside (NR) or nico-
tinic acid riboside (NAR) to NMN and NAMN, respectively. Dinucleotide formation, the single common step in all routes, is catalyzed by 
nicotinamide adenylyltransferase (NMNAT) yielding nicotinic acid adenine dinucleotide (NAAD) from NAMN or nicotinamide adenine 
dinucleotide (NAD) from NMN. Finally, NAD synthetase (NADS) converts NAAD to NAD in an amidation reaction using glutamine as 
substrate. The amide group of nicotinamide related structures is highlighted in blue, the carboxyl group of nicotinic acid related structures is 
highlighted in red. 
nucleoside precursors. Nicotinamide (Nam) and its deami-
dated form nicotinic acid (NA) are converted to nicotinamide 
mononucleotide (NMN) and nicotinic acid mononucleotide 
(NAMN) by Nam- or NA phosphoribosyltransferases 
(NamPRT and NAPRT), respectively. Both enzymes utilize 
5-phosphoribosyl-1-pyrophosphate (PRPP) as co-substrate. 
Similarly, QA is converted to NAMN by QA phosphoribo-
syltransferase (QAPRT). Alternatively, nicotinamide ri-
boside (NR) and nicotinic ac d ribosi e (N R are p os-
phorylated to the corresponding mononucleotide, NMN and 
NAMN, by nicotinamide riboside kinases (NRKs). The sub-
sequent dinucleotide formation is catalyzed by NMN 
adenylyltransferases (NMNATs) yielding NAD or its deami-
dated form, nicotinic acid adenine dinucleotide (NAAD). 
Finally, NAAD is converted to NAD by NAD synthetase 
(NADS).  
The use of different NAD biosynthetic routes varies 
among species. For example, several organisms such as flies 
and worms do not exhibit QAPRT activity and therefore 
have to rely on Nam or NA [9]. Moreover, while some or-
ganisms including humans use several alternatives to gener-
ate NAD, others, for example bacteria and yeast, depend on 
the route from NA via NAAD due to absence of NamPRT 
activity [9]. In the latter organisms, nicotinamidase (NADA) 
enables the utilization of Nam by deamidation to NA. It was 
speculated that these pathways could be mutually exclusive 
to avoid futile competition for Nam between NamPRT and 
NADA activities [9]. However, analyses of sequenced ge-
nomes suggest that at least some organisms exist in which 
both NamPRT and NADA are present [10], but the predicted 
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Indeed, TDO is highly expressed in the liver, the primary site of L-tryptophan 
catabolism, while IDO is ubiquitously expressed in extrahepatic tissues with the 





Figure 8. Reaction pathway for the quinolinic acid synthesis in humans. Abbreviation used: 
TDO, tryptophan 2,3-dioxygenase; IDO, indoleamine 2,3-dioxygenase; 3-HK, 3-hydroxy-L-
kynurenine; 3-HAA, 3-hydroxy-anthranilic acid; ACMS, a-amino-b-carboxy-muconate-e-
semialdehyde; ACMSD, α-amino-β-carboxymuconate-e-semialdehyde decarboxylase (modified 
from ref. 29). 
 
 
Moreover, TDO and IDO functions have been associated with different 
physiological and pathological conditions. For example, IDO is involved in the 
immuno-regulating system (29). The three-dimensional structures of both these two 
heme-containing dioxygenases have been solved, providing the structural basis to 
understand the chemistry of their mechanism of catalysis (30, 31). Briefly, N-
formylkynurenine is subsequently converted in four individual steps to the unstable 
α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMS), which can 
undergo either enzymatic conversion directed to total oxidation or non enzymatic 
cyclisation to quinolinic acid (4, 32). Interestingly, kynurenine 3-monooxigenase 
reaction product, 3-hydroxykynurenine (3-HK), induces an H2O2-neurotoxicity in 
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the central nervous system, and thus this enzyme has become an attractive 
pharmacological target (29). Although human kynurenine 3-monooxigenase 
crystallization was not achieved, Saccharomyces cerevisiae orthologue structure 
was determined (sharing 38% of sequence identity with the human enzyme) and 
validated as a template for structure-based drug design (33). The reaction 
representing the entry point into NAD+ biosynthesis from aminoacid catabolism is 
catalysed by QAPRTase and converts QA to nicotinic acid mononucleotide 
(NAMN) (Figure 7). This conversion represents the second rate-limiting step in the 
de novo pathway and consists in QA phosphoribosylation, using 5-phophoribosyl-
pyrophosphate (PRPP) as co-substrate, followed by its essentially irreversible 
decarboxylation (25). Determination of the human QAPRTase structure helped to 
establish the correct substrate binding mechanism with QA binding occurring first, 
and PRPP immediately after. Moreover, structural analysis has shown how the 
active site is formed at the dimer interface and it is located within the α/β barrel 
domain, whose composition ascribes QAPRTase to the type II phosphoribosyl-
transferases (34, 35) (Figure 9). As in the case of kynurenine 3-monooxigenase, 
also the product of QAPRTase reaction, QA, is neurotoxic and its imbalace has 
been observed in various neurophatological conditions. Thus, by shuttling QA to 
NAD+ biosynthesis, QAPRTase exerts also a neuroprotective effect (25). Finally, 
NAMN formed by QAPRTase converges to the Preiss-Handler pathway leading to 
NAD+, as described in the next session 1.1.2. In contrast to the other two 
phosphoribosyltransferases involved in NAD+ biosynthesis in humans, NMPRTase 
and NaPRTase, QAPRTase does not require ATP (25). Even though its importance 
has been stressed by the human disease pellagra, tryptophan alone is insufficient to 
support physiological NAD+ concentration (26) in a large majority of mammalian 
organs. 
  




Figure 9. Quaternary structure of human quinolinic acid phosphoribosyltransferase 
(hQAPRTase). (35). Human QAPRTase exists and functions as a hexamer in solution.  
 
 
1.1.2 Salvage pathways 
 
Although NAD+ can be synthesized de novo from tryptophan, it is assumed that 
the main source of NAD+ is from salvage pathways, which require the uptake of 
other NAD+ precursors from diet (4). Na and Nam are considered salvageable 
NAD+ precursors and were identified as the “anti-black tongue factor” in dogs 
with pellagra symptoms in late 1930s. They are collectively termed niacin, despite 
the fact that the biosynthetic pathways through which Na and Nam are used by 
cells are not the same. In 1958, Preiss and Handler discovered the existence of an 
alternate pathway of NAD+ biosynthesis from nicotinic acid in human 
and PHT complexes in structures from other sour-
ces.23,25 PHT is a competitive inhibitor of QPRT and a
carbocyclic analogue of QA. Nevertheless, the binding
sites for both molecules are the same. The QA/PHT
binding site is in a deep, yet solvent accessible pocket
composed of residues that create a positively charged
electrostatic surface. Th s positive c arge helps in balan -
ing the charge from two carboxylates in PHT. The sur-
face is composed of three arginine residues, R138, R161,
and R102* (* signifying that this residue is from adjacent
subunit of a dimer); two lysine residues, K139 and K171;
and one histidine residue, H160. These residues are con-
served in sequence as well as in their conformation in
QPRT structures from other sources23,25 (see Support-
ing Information Fig. S1), including in the previously
reported structure of human QPRT.26 In addition to
these highly conserved positively charged residues in our
crystal structure we observe a van der Waals surface that
interacts with the carbocyclic ring of PHT via residues
S248, S268, T137, M169, and E246. In a previous struc-
ture of human QPRT, a tartrate molecule present in the
active site precluded the formation of relevant complexes
in the crystal. Therefore, our work represents the first
report of human QPRT with a substrate analogue bound
in the active site.
Interactions between human QPRT and PHT
QPRT interacts with its substrate QA or its analogue
PHT via an elaborate network of hydrogen bonds and van
der Waals interactions. A total of thirteen hydrogen bonds
formed between QPRT and the carboxylate moieties of
PHT [Fig. 2(A)]. The C3 carboxylate group of PHT is
involved in eight hydrogen bonds, one of which is with a
water molecule. Four of these hydrogen bonds are formed
with side chain atoms NH2 and NE of R161, two with
side chain atoms NH1 and N of R138 and one with side
chain atom NZ of K171. The C2 carboxylate group partic-
ipates in five hydrogen bonds. Two of these are with the
main chain nitrogens of R138 and K139 and one with
side chain NZ of K171. Arg102 of the adjacent subunit of
the QPRT dimer forms the remaining two hydrogen
bonds through its side chain NH1. These observations are
consistent with those previously reported for M. tuberculo-
sis23 and S. cerevisiae25 structures.
In addition to hydrogen bonding network, we
observed an extensive network of van der Waals contacts
between PHT and QPRT [Fig. 2(B)]. We observe all six
carbon atoms in the PHT ring making contacts with resi-
dues in and around the active site. In addition to the
ring carbon atoms the carboxyl carbon and oxygen
atoms also form part of the van der Waals network. A
total of 48 such contacts can be observed out of which
21 are through ring carbon atoms, 10 through carboxyl
carbon atoms and 17 through the carboxyl oxygens. In
the QPRT structure the residues that form these van der
Waals contacts include three arginine residues (R138,
R161, and R102*), two lysines (K139 and K171), two ser-
ines (S248 and S268) and one each of threonine (T137),
histidine (H160), methionine (M169), and glutamic acid
(E246). Residues corresponding to T137 and H160 (Sup-
porting Information Fig. S1) have been implicated in van
der Waals interactions in M. tuberculosis QPRT struc-
ture.23 Taken together, these observations suggest that
van der Waals interactions play an important role in ori-
entating and stabilizing QA in the QPRT active site.
Figure 1
Structure of hQPRT (A) Ribbon diagram of the hQPRT hexamer (six subunits in different colors). Hexameric hQPRT is composed of a “trimer of
dimers”; the fundamental repeating unit is a homodimer. (B) All six subunits of hexamer bind substrate in the substrate binding pocket. The QA/
PHT binding site is buried deep within this pocket.
S.S. Malik et al.
408 PROTEINS
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erythrocytes. In particular, they showed how incubation of nicotinic acid-C14 with 
human erythrocytes resulted in synthesis of two radioactive nucleotides identified 
as nicotinic acid mononucleotide (NaMN) and nicotinic acid dinucleotide (NAAD), 
respectively. They also showed that NAAD-C14 formation in vivo occurred before 
NAD-C14 formation, concluding that the last step of NAD+ synthesis from 
nicotinic acid consisted of the amidation of NAAD into NAD+ (36). Immediately 
after, Preiss and Handler identified the three enzymes required to accomplish 
synthesis of NAD+ from Na (37). The first rate-limiting reaction of this three-step 
pathway, now known as Preiss-Handler pathway, is catalysed by Nicotinic acid 
phosphoribosyltransferase (NaPRTase). It catalyses the conversion of Na to 
NAMN using PRPP as phosphoribosyl donor and releasing pyrophosphate (PPi). 
The human NaPRTase is matter of interest of this thesis and will be abundantly 
discussed in Chapter 3. The second step in the Preiss-Handler pathway is the 
conversion of NaMN to NAAD in presence of ATP, catalysed by one of the 
nicotinamide mononucleotide adenylyltransferases isoforms, NMNAT1, NMNAT2 
or NMNAT3, identified in humans (38-40). NaMN deriving from the de novo 
pathway enters the Preiss-Handler pathway at this point. NMNAT activity 
represents the single universal common reaction in all NAD+ biosynthetic 
pathways (Figure 7), thus, it has been immediately recognized as an attractive 
target for the development of antibacterial drugs. The expression of the three 
human isoforms of NMNAT is ascribed to different cellular compartments, with 
NMNAT1 being a nuclear enzyme, NMNAT2 and NMNAT3 localising to the 
Golgi apparatus and the mitochondria, respectively (41). The crystal structures of 
human NMNAT1 (42) and NMNAT3 (43) have been solved, while only structural 
models are available so far for NMNAT2. Interestingly, the human enzymes 
display a unique dual specificity being able to recognize with the same efficiency 
both NaMN and NMN as substrates. The ATP-dependent amidation of NAAD to 
NAD+ represents the final step in the Preiss-Handler pathway and it is catalysed by 
NAD synthetase (NADS). As for the NMNAT reaction, also this step is shared 
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with the de novo biosynthesis. The human NADS uses glutamine as amide donor, 
and it is composed of two protein domains. The C-terminal domain is responsible 
of the amide transfer onto NAAD, whereas the N-terminal domain catalyses the 
glutamine hydrolysis. The structural determination of Mycobacterium tuberculosis 
NADS, another glutamine-dependent NADS, revealed the existence of a tunnel of 
communication between the two domains, of about 40 Å, that permits the transfer 
of the amide group generated in the N-terminal domain towards the C-terminal 
domain (25, 44). The other niacin-derived molecule Nam is the product of all 
NAD+-consuming reactions and it is saved distinctly from Na. In vertebrates, the 
intracellular Nam salvage pathway depends on a nicotinamide phosphoribosyl-
transferase (NMPRTase), which entered the literature with the names pre-B cell 
colony enhancing factor (PBEF) (45) and Visfatin (46). Intracellularly, NMPRTase 
catalyses the phosphoribosyl transfer from PRPP onto Nam and yields NMN and 
pyrophosphate. Whether its extracellular counterpart PBEF/Visfatin is endowed of 
phosphoribosyltransferase activity is still matter of debate (47, 48), though it was 
reported that PRPP and NMN are virtually absent in mouse plasma (48). 
NMPRTase possesses a facultative ATPase activity that allows the production of 
NMN at products/substrates ratios thermodynamically forbidden in the absence of 
ATP. Indeed, by coupling ATP hydrolysis to NMN synthesis, the catalytic 
efficiency of the system is improved 1100-fold and substrate affinity dramatically 
increased for both substrates. Moreover, NMPRTase undergoes feedback inhibition 
by both NAD+ and NADH (49). As a growth factor, a cytokine and an enzyme, 
NMPRTase plays pleiotropic physiological functions, as suggested by its 
ubiquitous tissue distribution, and its dysregulation is implicated in several human 
diseases, including cancer. Indeed, NMPRTase overexpression has been found in 
many tumour cells and several studies have indicated that NMPRTase may be an 
attractive diagnostic and drug target for cancer therapy (50, 51). Several potent 
NMPRTase inhibitors, such as FK866, have been identified (52). Human 
NMPRTase structure has been determined (53) as well as the molecular basis of its 
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inhibition by FK866 (54). After the NMPRTase reaction, NMN is converted to 
NAD+ by NMNAT. Ten years ago, nicotinamide riboside (NR) was discovered as 
an additional salvageable NAD+ precursor vitamin. By observing that NR was 
already known to be a NAD+ precursor in bacteria such as Haemophilus 
influenzae, Bieganowsky and Brenner demonstrated how NR could also function as 
precursor of the pyridine nucleotide in Saccharomyces cerevisiae, through a 
previously unknown route to NAD+. In this pivotal study, Bieganowsky and 
Brenner employed a genetic approach based on the use of mutant yeast strains, and 
noticed that NR supplementation was capable to rescue the growth of mutants 
carrying the lethal deletion of QNS1. The latter is the yeast orthologue of NADS, 
catalysing the final NAD+ biosynthetic step, common to all pathways known until 
then in S.cerevisiae. At the same time, the molecular identity of the conserved NRK 
genes, encoding for the enzymes responsible for the phosphorylation of NR to 
NMN, was also identified (55). In humans, there are two isoforms of NRK, namely 
NRK1 and NRK2, that show both high specificity for phosphorylation of NR and 
the anticancer drug tiazofurin (55). Nevertheless, NRK1 can utilise either ATP and 
GTP as phosphodonor, while NRK2 is an ATP-specific kinase (56). Human NRK1 
and NRK2 could use as substrate also the deamidated form of NR, Nicotinic acid 
riboside (NaR), that was demonstrated to be utilised in yeast as a NAD+ precursor 
in a novel biosynthetic pathway that depends on NRK and NADS (56). The 
structures of NRK1 in complex with substrates and products have been determined 
(56, 57) while NRK2 structure has yet to be solved. In summary, in human cells 
NaR and NR are converted to NAD+ in a three-step and two-step pathway, 
respectively (Figure 7). In the first step, NRK converts NaR to NaMN and NR to 
NMN. Subsequently, NaMN enters the Preiss-Handler pathway while NMN is 
directly deamidated to NAD+ by NMNAT. A second NRK-indipendent NR 
salvage pathway has been described in yeast (58), even if it has yet to be 
investigated in mammalian systems. In conclusion, all NAD+ salvage pathways as 
well as the de novo pathway after QA synthesis, share a common scheme towards 
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NAD+ formation, that consists first in the formation of a pyridine mononucleotide 
and then in the dinucleotide formation. Indeed, from five different precursors (QA, 
Nam, NA, NR and NaR) we assist at the synthesis of two intermediates, NAMN 
and NMN, that are subsequently converted, in a common step, to NAAD and 
NAD+, respectively. Finally, as previously discussed, NAAD undergoes an 
additional step of amidation to form NAD+ (25).  
 
 
1.1.3 NADP+ biosynthesis  
 
Some of the cellular NAD+ is converted into NADP+ by NAD Kinase (NADK), 
that catalyses the transfer of a phosphate group from ATP to the 2’ position of the 
adenosine ribose of NAD+, thus forming NADP+ and ADP (59) (Figure 10A). 
This reaction represents the only known way to generate NADP+ in all living 
organisms (29). NADK plays a key role in the regulation of the cellular redox state, 
by modulating the levels of NAD and NADP, and provides the substrate for many 
important metabolic reactions and for the formation of the second messenger 
NAADP. Surprisingly, despite the fundamental role of NADK, only a single 
isoform of NADK has been found in mammals so far. Lerner and coworkers 
identified the human NADK cDNA in 2001, immediately after the identification of 
the protein sequences of Micrococcus flavus and Mycobacterium tuberculosis 
NADKs (60, 61).  
  




Figure 10. A. NAD Kinase-catalysed reaction (59). B. Physical and Kinetic Properties of 
human NAD Kinase (61). 
 
 
The human gene was shown to be expressed mostly in every tissue but not in 
skeletal muscle. The recombinant human enzyme was expressed in E. coli and was 
shown to be highly selective for the substrates NAD+ and ATP, showing Km 
values of 0.54 and 3.33 mM, respectively (Figure 10B). It requires a divalent 
cation to function but is not calmodulin/Ca2+ dependent, in contrast with the 
enzyme purified from neutrophils that was shown to be dependent from these 
effectors (59, 61). Also on the basis of this difference, further studies have been 
encouraged to exclude the existence of other NADK isoforms. As for its primary 
sequence being determined on the basis of the precedent work on the bacterial 
M.tuberculosis enzyme, also the first three-dimensional structure that was 
determined has been the M.tuberculosis NADK (62). The interest for the 
M.tuberculosis NADK was especially due to the fact that this enzyme is essential 
for the growth of the multidrug-resistant pathogen, thus representing an attractive 
A" B"
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The first pyridine dinucleotide to be 
isolated and chemically characterized is 
NADP, the phosphorylated form of NAD. In 
the 30s, Warburg and Christian isolated and 
purified a cofactor termed “Coferment II” 
involved in the reaction catalyzed by the 
enzyme glucose-6-phosphate dehydrogenase 
[1]. These authors quickly determined that 
NADP contained two bases, three phosphates 
and two riboses [1]. The two bases were 
identified as adenine and nicotinamide, 
respectively, and the three phosphates were 
erroneously thought to be linked through 
phosphoanhydric bonds. Only twenty years 
later, Kornberg and Pricer determined the 
correct structure, with the third phosphate on 
the 2’ position of the adenylic acid moiety [2]. 
NADP is a vital dual function cofactor 
that is intimately involved in both energy and 
signal transduction [3]. The cofactor NADP is 
indeed a key molecule in most reductive 
biosynthetic reactions and it is an important 
constituent of cellular defence mechanism 
against oxidative stress [4-7]. In living 
organisms it is synthesized by the enzyme 
NAD kinase (EC 2.7.1.23), which 
phosphorylates NAD at the 2’ position of the 
adenosine ribose, in the presence of Mg+2 and 




kinase cDNA. In several tissues a minor band of ap-
proximately 1.8 kb of unknown origin was also labeled.
NAD kinase appears to be equally expressed in most
tissues. However, no expression of NAD kinase was
detected in skeletal muscle and only little in small
intestine tissue. In placenta a significantly enhanced
expression was observed.
Studies of bacterial NAD kinases revealed that these
enzymes consist of polypeptides with a subunit molec-
ular mass of 30–35 kDa (20, 21) as opposed to 49 kDa
of the human enzyme. Moreover, the yeast and E. coli
enzymes exist as hexamers (21, 22), whereas the hu-
man protein apparently consists of only four subunits
that form the catalytically active enzyme. This conclu-
sion was drawn from gel filtration experiments (Fig. 3).
Similar to the recombinant human NAD kinase, the
partially purified bovine enzyme also exhibited na-
tive molecular mass of about 200 kDa (Fig. 3). The
molecular masses of he recombin nt human enzyme
and the partially purified bovine liver enzyme were
calculated to be abou 190 and 210 kDa, respectiv ly.
Analyses of the catalytic properties of the recombi-
nant human enzyme (Table 1) established that the
substrate affinities for ATP (KM ! 3.3 mM) and NAD
(KM ! 0.54 mM) are similar to values previously re-
ported for the enzyme from bovine liver and other
animal tissues (23). The specific activity was calculated
to be 6.7 !mol (min " mg)#1. Both the recombinant
human enzyme and bovine liver NAD kinase exhibited
similar characteristics regarding the dependence of
their catalytic activities on pH and temperature (Table
1). Both enzymes are quite resistant to heat treatment.
This is indicated by the rather high temperature opti-
mum of about 55°C (Table 1). Moreover, incubation at
60°C for 5 min resulted in a minimal loss ($5%) of
activity. The pH optimum is in the alkaline range (pH
7–8). Under acidic conditions (pH $ 5.5), the enzyme is
readily inactivated.
Both the human and the bovine enzymes required
divalent cations for their catalytic activity. That is,
presumably the substrate nucleotides need to be com-
plexes with bound divalent metal ions. The optimal
concentration of Mg2%-ions was about 10 mM. Several
other metal ions were also efficient in supporting the
catalytic activity (Table 2). In fact, zinc and manganese
ions were preferred over Mg2%. Copper and nickel ions
were not accepted.
Human NAD kinase appears to be highly selective
for its substrates, NAD and ATP. Although ATP could
be replaced by dATP, the specific activity using GTP as
phosphoryl donor amounted to less than one tenth of
that measured in the presence of ATP (Table 3). None
of the NAD analogs tested was phosphorylated in the
presence of ATP under the assay conditions used. That
is, modification of either the purine or the nicotinamide
FIG. 3. Molecular weight determination of catalytically active
bovine and recombinant human NAD kinases. Gel filtration of par-
tially purified bovine liver or recombinant human NAD kinase was
conducted as described under Materials and Methods. The proteins
used for calibration (circles) were thyroglobulin ( 69 kDa), ferritin
(440 kDa), glutamic acid dehydrogenase (336 kDa), alcohol dehydro-
genase (150 kDa), bovine serum albumin (67 kDa), and cytochrome c
(12.3 kDa). The molecular weight of NAD kinases was calculated
according to the elution volume of fractions containing NAD kinase
activity.
TABLE 1









Vmax 6.7 !mol (min " mg protein)#1
Temperature optimum 55°C
pH optimum 7.5 (7.0–8.0)
Note. NAD kinase activity was assayed by the enzymatic proce-
dure as described under Materials and Methods.
TABLE 2
Influence of Metal Ions on the Catalytic Activity








Note. NAD kinase activity was assayed by the enzymatic proce-
dure described under Materials and Methods in the presence of 1
mM indicated metal ion. The activities (in %) are given related to
that measured in the presence of 1 mM Mg2%. In the absence of
divalent metal ions, no activity was detected. n.d., no detectable
activity.
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target for novel antitubercular agents. Nowadays, a pdb entry (3PFN) for the 
human enzyme has been deposited in the Protein Data Bank, but no descriptions 
have been reported so far. The comparison of the human and M.tuberculosis 





1.2 Systemic features of NAD homeostasis  
 
Not only the multiple NAD+ biosynthetic pathways and the breathtaking number of 
NAD(P)+-consuming reactions, but also the compartmentation of both enzymes 
and NAD metabolites, and their transport among the organelles and between the 
extracellular and intracellular spaces (NAD influx/efflux), critically influence the 
maintenance of NAD homeostasis in human cells. Moreover, the availability of 
NAD(P) may depend on the type of cell and its contingent conditions such as, 
metabolic and redox state, as well as stress and other environmental stimuli, and it 
plays a pivotal role in the determination of the pathophysiological functions of the 
cell (6). It is therefore not surprising that NAD homeostasis must be tightly 
regulated (63) even though, the mechanisms through which all these regulation 
determinants influence each other still arise challenging questions. The 
compartmentation of NAD(P) is reflected by a distinct spatial organization of the 
multitude of NAD(P)+-dependent signalling pathways (6) (Figure 11). To better 
understand the presence of the distinct NAD pools, Nikiforov and co-workers have 
elegantly determined the subcellular localization of NAD+ biosynthetic enzymes. 
They used a new detector system, based on the addressing of the catalytic domain 
of PARP1 (PARP1cd) to the mitochondrial matrix, to monitor the organellar 
changes in NAD content through the immunodetectable formation of PAR. (26). 
Although NAD+ is synthesized mainly in the cytosol, nucleus and mitochondria, it 
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has been detected also in vescicular and extracellular compartments (6). Indeed, 
distinct subcellular NAD pools have been identified also in the endoplasmic 
reticulum, Golgi complex and peroxisomes (64, 65). All these NAD pools are 
subjected to variations within the cells and their relative differences can vary in a 
cell type-specific manner (66). The NAD pool in mitochondria has received 
particular attention (26, 67, 68) because of the crucial functions for cellular energy 
metabolism played by these organelles and their dysfunction being associated with 
a large number of diseases. Mitochondrial NAD pool appears to be sufficiently 
robust to preserve cell viability and ATP levels and there is a growing body of 
evidence suggesting that mitochondria are endowed of their own NAD+ 
biosynthetic machinery (67). Indeed, a mitochondrial isoform of NMN 
adenylyltransferase, NMNAT3 has been identified (69) and localised to the 
mitochondrial matrix (26). Furthermore, the same study that has assigned 
NMNAT3 to the mitochondria, has also shown how NMN is the cytoplasmic 
precursor of mitochondrial NAD, solving the long standing problem of NAD 





Figure 11. Compartmentation of NAD+ and NAD+ converting enzymes (6). The concentration 
of NAD+ is high in mitochondria (~ 400 µM) intermediate in the nucleus and cytosol (~ 100 µM) 
and low (<1 µM) in the extracellular space.  
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Another field that has elicited intensive investigation regards the extracellular NAD 
“reservoire” and how the extracellular NAD+ precursors and intermediates may 
serve for intracellular NAD+ biosynthesis. This topic includes the unravelling of 
the complex transport system of NAD metabolites inside and among the cells. 
Vitamin B3 NAD+ precursors Na e Nam are provided with the diet and enter the 
bloodstream for distribution to tissues (70). NR has been detected in cow milk (55) 
and it is presumed to be translocated from the extracellular to the intracellular 
compartment by a nicotinamide riboside transporter (Nrt), currently unidentified in 
mammals (71). NMN levels have been detected in mouse plasma (47) but its 
formation by the extracellular form of NMPRTase (eNAMPT) is still matter of 
debate (47, 48) and its transport through the plasma membrane has not been 
elucidated so far. Extracellular NAD+ has been detected in plasma and fluids (72, 
73) at low concentration (Figure 11) and it can cross the plasma membrane 
through Cx43 hemichannels (74). Although its uptake has been postulated in some 
human cell lines (73), other studies support the idea that nucleosides, but not 
nucleotides can go through the plasma membrane, unless cell-type specific 
transport systems are present (26). This last hypothesis is consistent with the 
generally accepted idea that plasma membrane is impermeable to phosphorylated 
molecules. At the end of the last century, it had already been described a multitude 
of ecto-enzymes hydrolysing extracellular ATP and other nucleotides in order to 
inactivate intercellular signalling via extracellular nucleotides (e.g. purinergic 
signalling) and recycle the hydrolysis products (75). These enzymes are expressed 
differently on the plasma membrane of various human cells and tissues and include 
a family of ecto-phosphodiesterases/pyrophosphatases possessing a surprisingly 
broad substrate specificity, being capable of hydrolysing also NAD+ to AMP and 
NMN (76, 77). The multifunctional ecto-enzyme CD38 can hydrolyse not only its 
second messenger products, NAADP and cADPr, but also ADPr, ADPr phosphate 
(22) and NMN (78). After the hydrolysis of NMN by CD38 into Nam and 5’-
phosphoribose, Nam can thus enter the cells through the plasma membrane. Also 
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the presence of a lymphocyte surface protein, CD73, endowed with a 5’-
nucleotidase activity had been known for a long time (79). Indeed, this 
glycosylphosphatidylinositol (GPI)-anchored protein was well known to be 
responsible of the hydrolysis of nucleoside 5’-monophosphates, mainly AMP, to 
their respective nucleosides and Pi. It was only recently, after the determination of 
the crystal structure of the Haemophilus influenzae NAD nucleotidase (NadN) and 
the identification of CD73 as the human orthologue of this bacterial enzyme, that 
other features of CD73 have been explored (80). Indeed, Garavaglia and co-
workers demonstrated how CD73 could also hydrolyse NAD+ and NMN, thus 
disclosing a possible novel function of this enzyme in systemic NAD metabolism. 
In 2012, the crystal structure of the soluble form of CD73 (without the GPI anchor) 
has been determined indicating how a prominent domain motion may control the 
enzymatic substrate specificity (81). The potential novel role played by CD73 in a 
hypothesized extracellular NAD+ biosynthetic cycles in vertebrates, as delineated 
by Belenky in 2006 (3) (Figure 12), has found positive feedbacks in the 
experimental results of many studies (26, 80, 82). Firstly, it was shown how, when 
Nam salvage pathway was blocked in human cell lines, extracellular NMN 
utilisation as NAD+ precursor was prevented by the use of a competitive substrate 
(CMP) for the dephosphorylation reaction driven by the external 5’-nucleotidase. 
Thus, it was established that NMN (as well as the other nucleotides) has to be 
firstly converted to its corresponding nucleoside NR to serve as precursor for 
NAD+ biosynthesis (26). Grozio and collaborators demonstrated that CD73 
enables, while CD38 impairs, the utilization of extracellular NMN for NAD+ 
biosynthesis by converting it into NR and Nam, respectively (82). Investigations to 
measure NAD and its precursors and metabolites (NAD metabolome) may address 
the opening questions on the routes for NAD uptake in different human cells and 
provide a framework of what a particular cell or tissue is doing. So far, the major 
challenges to determine NAD pools content have been represented by the nature of 
the methods themselves, requiring cell disruption and thus possibly affecting the 
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organellar concentrations, and by their robustness and reproducibility that should 
take into account the high complexity of the samples. The PARAPLAY method 
(64) as well as new HPLC-MS methods (83) seem to bypass some of these 






Figure 12. A potential extracellular NAD+-cycle in vertebrate as delineated by Belenky et al. 
in 2006 (3). 
 
 
In conclusion, NAD homeostasis in human cells should be perceived as a dynamic 
state that is influenced by many intracellular and external factors finely 
interconnected, and regulated in response of the contingent physiological or 
pathological conditions of the cell of a determined tissue. Maintaining NAD 
homeostasis is essential for proper cellular function and aberrant NAD metabolism 
has been implicated in a number of metabolic- and age-associated diseases (84), 
including cancer. For example, there are different results supporting a relationship 
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between the NAD+-dependent sirtuins and cancer (18) and it is now well assessed 
that NMPRTase overexpression constitutes a potential biomarker for some cancer 
treatments (85). A look more and more in depth on the molecular basis of function 
and regulation of each of the metabolic and signalling processes discussed so far 
where NAD(P) plays the title role, without losing sight of the overall vision of the 
whole, so could offer important opportunities for the development of new therapies 
to maintain health and treat these various diseases. 
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Outline of the thesis 
 
NAD(P) is an essential electron carrier and a key molecule of signalling 
pathways. In bioenergetic pathways, NAD(P) serves as a coenzyme and it is 
reversibly converted between its oxidized (NAD(P)+) and reduced (NAD(P)H) 
states. The interchange within the redox couples is fundamental in determining the 
redox state of the cell, but do not require pyridine nucleotide consumption. In the 
guise of signal transducer, NAD(P)+ is involved in a variety of pivotal cellular 
processes, such as gene expression, calcium homeostasis, intercellular 
communication, cell death and aging. In this wide panorama of processes where 
pyridine nucleotide involvement goes beyond its coenzymatic activity, NAD(P)+ is 
used as a substrate and, therefore, consumed. In order to supply the cell with the 
pyridine nucleotides consumed in the signalling reactions and to meet its 
circumstantial needs, different pathways are responsible for NAD+ biosynthesis 
starting from several precursors in humans. Indeed, NAD+ biosynthesis is 
accomplished through either the de novo pathway from tryptophan or any of the 
salvage pathways that utilise the vitamin precursors of NAD+, namely 
nicotinamide (Nam), nicotinic acid (Na) and nicotinamide riboside (NR).  
Nicotinate phosphoribosyltransferase (NaPRTase) is the enzyme responsible for the 
synthesis of NAD+ from Na. It catalyses the first rate-limiting reaction of the 
ubiquitous three-step Preiss-Handler pathway where Na is converted to nicotinate 
mononucleotide (NaMN) using 5-phosphoribosyl-1-pyrophosphate (PRPP) as 
donor of the 5-phosphoribose.  
In the first part of my PhD dissertation, described in Chapter 3, I report on the 
structural determination of the human NaPRTase. We determined its three 
dimensional structure at 2.9 Å resolution in its free form. Both our structural 
analysis and molecular docking studies confirm that the minimal functional unit in 
human NaPRTase consists of a dimer. Indeed, the active site is formed at the dimer 
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interface with residues belonging to both monomers participating in ligand 
recognition and stabilisation. Moreover, overall structural analysis of hNaPRTase 
reveals that this enzyme belongs to the type II phosphoribosyltransferase 
subfamily. Structural comparisons with hQAPRTase and hNMPRTase, two other 
important phosphoribosyltransferases involved in NAD+ biosynthesis, show a 




NAD(P)+-consuming reactions are compartimentalised and distinct NAD pools 
exist, whose relative content may change depending on the type of tissue 
considered as well as the pathophysiological conditions of the cell. Therefore, in 
human cells, NAD homeostasis has a dynamic and systemic nature that is believed 
to be subject of a tight regulation, and its maintenance is essential for proper 
cellular functions. Besides NAD+ biosyntesis, also the availability of different 
NAD+ precursors and the mechanisms regulating their uptake from the 
extracellular space critically contribute to the NAD homeostasis maintenance. 
Several transporters and ecto-enzymes, differently distributed on the plasma 
membrane of the various human cells, mediate the internalisation of NAD 
metabolites. CD73 is a glycosilphosphatidylinositol (GPI)-linked cell surface 
human enzyme involved in NAD homeostasis through its 5’-nucleotidase activity. 
Indeed, CD73 mainly catalyses the dephosphorylation of extracellular purine and 
pyrimidine ribo- and deoxyribonucleoside monophosphates to their corresponding 
membrane-permeable nucleosides, but it can also process both NAD+ and NMN, 
with implications for uptake of these extracellular nucleotides.  
In the second part of this thesis, discussed in chapter 4, I present a biochemical 
investigation on the uptake mechanisms of nicotinamide mononucleotide (NMN) 
and NR in human hepatocarcinoma cell lines. We worked with wild type and 
knockdown CD73 HepG2 cells and fed them with double-labelled NR and NMN in 
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order to investigate their cellular uptake. Through the use of chemical biology tools 
and LC-MS2, our preliminary results confirm, in a direct manner, the dependency 
of extracellular NMN upon CD73 activity to be used as intracellular source of 
NAD+ in human hepatocytes. Moreover, this study offers a complete framework of 
the relationships among NAD metabolites regardless the extracellular precursor 
utilised by cells, demonstrating the utility of stable labelling experiments coupled 
to LC-MS/MS analysis to elucidate metabolic relationships.  
 
 
In summary, by determining the three-dimensional structure of hNaPRTase, a 
pivotal enzyme involved in NAD+ biosynthesis, and confirming the availability of 
extracellular NAD+ precursors to the intracellular pool, the results discussed in this 
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Human nicotinic acid phosphoribosyltransferase (EC 2.4.2.11) (hNaPRTase) is 
the rate-limiting enzyme in the three-step Preiss-Handler pathway for the 
biosynthesis of NAD+. It catalyses the conversion of nicotinic acid (Na) to 
nicotinic acid mononucleotide (NaMN), using 5-phosphoribosyl-1-pyrophosphate 
(PRPP) as phosphoribosyl donor and releasing pyrophosphate (PPi). Several 
studies have underlined NaPRTase importance for NAD homeostasis in mammals, 
but no crystallographic data have been available so far for higher eukaryotes. 
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Here, the three-dimensional structure of a recombinant hNaPRTase is reported. 
The human enzyme was overexpressed in Escherichia coli and its crystal structure 
was solved by means of molecular replacement at a resolution of 2.9 Å in its free 
state. Our structural data reveal that hNaPRTase functions as a dimer. Indeed, the 
active site formation occurs at the dimer interface and requires the participation, on 
each monomer, of an irregular α /β barrel that ascribes hNaPRTase to the Type II 
phosphoribosyltransferase subfamily. Furthermore, due to the absence of co-
crystallized ligands within hNaPRTase, we performed molecular docking 
simulations to better understand the catalytic mechanism of the enzyme. We 
identified residues involved in the recognition and stabilisation of several ligands, 
and confirm their belonging to both monomers. Interestingly, among all available 
NaPRTase structures, we found that hNaPRTase is more similar to E. faecalis 
NaPRTase. We postulated a possible adaptation mechanism for the commensal 
bacterium to survive in the human small intestine, where hNaPRTase is highly 
expressed. Moreover, structural comparisons of hNaPRTase with the other two 
human Type II phosphoribosyltransferases involved in NAD+ biosynthesis, 
hQAPRTase and hNMPRTase, reveal that the three enzymes show a similar overall 
structure in accordance with their common function. Nevertheless, they also 
present important structural differences. In particular, as previously reported for 
TaNaPRTase, we show that hNaPRTase active site lacks of a tunnel that, in 
hNMPRTase, represents the binding site of its potent inhibitor FK866, currently 












Nicotinamide adenine dinucleotide (NAD) and its phosphorylated form (NADP) 
are essential and ubiquitous coenzymes, which play a fundamental role in cellular 
metabolism. Beyond its pivotal role as a redox cofactor in energy transduction and 
cellular metabolism, NAD(P) is also intimately involved in signalling pathways. 
Indeed, in the last years NAD(P) has emerged as a major topic with a wealth of 
biochemical investigations that confirmed its central role in a plethora of 
physiological and pathological conditions (1, 2). The NAD(P) derivatives, nicotinic 
acid adenine dinucleotide phosphate (NaADP) and cyclic ADP-ribose, are likewise 
among the most potent calcium-mobilising agents. NAD+ is the substrate for 
poly(ADP-ribosyl)ation, a vitally important post-translational modification 
occurring within the nuclei of higher eukaryotes by poly(ADP-ribose) polymerase. 
Also, NAD+ is the substrate for mono-ADP-ribosyltransferase, an enzyme that 
transfers a single ADP-ribose unit from NAD+ onto target proteins in both 
mammalian and prokaryotic cells. Moreover, overexpression of the NAD+ 
biosynthetic pathway enzymes, were shown to extend yeast cell lifespan, a 
phenomenon linked to the action of NAD+-dependent catalysis of protein 
deacetylation (3-7). Severe altering of NAD homeostasis features a number of 
pathological conditions ranging from neurological disorders, cancer and infectious 
diseases, and is also observed in the process of ageing (8). Consequently, all these 
NAD+-degrading reactions clearly necessitate permanent regeneration of the 
cofactor (9). Based on the literature data, it is possible to identify four different 
substrates that can be used as a source of the pyridine ring in the NAD+ 
biosynthesis: Quinolinic Acid (QA) in the de novo pathway; Nicotinic Acid (Na) 
and Nicotinamide (Nam) in the salvage pathways; Nicotinamide Riboside (NamR) 
in the “Preiss-Handler-independent” pathway (2). The three precursor QA, Na and 
Nam can be transferred onto 5-phosphoribosyl-1-pyrophosphate (PRPP) by the 
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respective phosphoribosyltransferase. The resulting, Nicotinic Acid 
Mononucleotide (NaMN) and Nicotinamide Mononucleotide (NMN), are 
converted in their corresponding dinucleotides: Nicotinic Acid Dinucleotide 
(NaAD) and NAD+ by Nicotinamide Mononucleotide Adenylyltransferase 
(NMNAT) (10). Finally NaAD is amidated to NAD+, by NAD synthase (Figure 1) 
(11, 12).  
Although Nam has been thought to represent the main precursor of the salvage 
synthesis to keep cellular contents of NAD+ constant in mammals (13), the 
supplementation of Nam does not seem so effective in elevating cellular NAD 
content beyond the basal concentrations (14). Indeed, Nam levels are much higher 
than Na levels throughout mammalian living cells, but some tissues preferentially 
use Na for NAD+ synthesis (15). Effectively, Na was found to be more successful 
than Nam in increasing NAD+ levels in heart, kidney (16), and red blood cells (17). 
Therefore, both precursors appear relevant for NAD+ biosynthesis, possibly with 
distinct and complementary roles in different cells. Moreover, in a recent work it 
was demonstrated that Na added to stress-induced damaged human cells, reversed 
the H2O2-cytotoxicity in a dose dependent manner. In contrast, the addition of 
corresponding concentration of Nam to the culture medium did not protect the cell 
from the stress (18).  
In mammals, Na is mainly extracellular and derives directly from the diet, and 
indirectly from dietary Nam by a gut flora Nam deamidase. As shows in Figure 1, 
Na is the substrate of a Nicotinate Phosphoribosyltransferase (NaPRTase, EC 
2.4.2.11), originally named NaMN pyrophosphorylase, which catalyses the 
synthesis of NaMN from Na and PRPP. Handler first identified the enzyme 
NaPRTase in humans together with the different ability of Na and Nam to elevate 
NAD+ levels in red blood cells. The enzyme has also been partially characterised 
from different sources: prokaryotes, archaea, and eukaryotes indicating the 
ubiquitous nature of the biosynthetic pathway from Na to NAD+, the so-called 
“Preiss-Handler pathway” (19-22). The hNaPRTase significance for NAD cellular 
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homeostasis in mammals has been reinforced by the indication that in the human 
embryonic kidney cells (HEK293) the addition of Na, but not Nam, markedly 
elevates NAD+ levels. Moreover, there is evidence that hNaPRTase appears to be 
more expressed in those tissues where Na is the preferential source for NAD+ 
biosynthesis (18). This Na effect could be ascribed to the finding that NaPRTase, 
unlike NamPRTase, is not subject to feedback inhibition by NAD+ (18). The 
ability of orally administered Na to increase cellular NAD+ levels via hNaPRTase 
may also account for some of its vitamin effects (17). Indeed, this awareness 
suggested novel applications for the treatment of conditions associated with cellular 
NAD+ depletion, such as in photodamaged skin (23). Furthermore, Na represents 
one of the oldest lipid-modifying drugs, showing a unique anti-lipolytic effect (24). 
This action is mediated by its interaction with GPR109A, a Na-receptor on the 
plasma membranes of adipocytes (25, 26). The investigation on the possible 
modulation of blood Na levels by hNaPRTase in treated patients, based on the 
enzyme characteristics could optimize current pharmacological applications of the 
vitamin in this important metabolic contest. Like bacterial enzymes, human 
NaPRTase is strictly specific for Na as a substrate. In contrast, its activity is not 
affected by the presence of NaMN, ADP, NAD+ and NaAD+ (24), and 
consequently the lack of inhibition by NAD+ supports the ability of Na to elevate 
NAD+ levels via the “Preiss-Handler pathway”. Otherwise, with respect to ATP 
requirement, NaPRTases have been grouped in three distinct classes: strictly ATP-
dependent, strictly ATP-independent, or independent but stimulated by ATP (11). 
In this contest, ATP is cleaved to ADP and Pi stoichiometrically with respect to 
NaMN formation (28, 29), and the activation of NaPRTase by ATP is 
conformationally coupled to the product formation via a phosphoenzyme 
intermediate (30, 31). Indeed, it was demonstrated that NaPRTase showed to be 
autophosphorylated in S. typhimurium (32) and the activity of the human 
NaPRTase mutant H213A resulted not stimulated but rather inhibited by ATP. This 
inhibition was found to be non-competitive with respect to Na but competitive with 
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respect to PRPP consistent with the ATP occupancy of the PRPP binding site as 
also demonstrated in S. typhimurium NaPRTase (33). In particular, human 
NaPRTase has a dimeric organisation and ATP utilisation might promote allosteric 
interactions between subunits. Such ATP-driven conformational change can also be 
inferred by the observation that, in microbial NaPRTases, ATP binding protects 
from proteolysis (34) and heat inactivation (35). In addition, the effect of inorganic 
Pi on human NaPRTase activity results in an increasing of the Kcat value of about 
25-fold without altering substrate affinity (33). Besides ATP and Pi, several central 
compounds of cellular metabolism appear to affect human NaPRTase. The enzyme 
is indeed activated by DHAP and pyruvate and inhibited by CoA (and its 
derivatives acetyl-, glutaryl- and succinyl-CoA), G3P, phosphoenolpyruvate, and 
fructose 1,6-bisphosphate, leading to hypothesize a link between NAD+ synthesis 
and glucose or/and fatty acid metabolism (33). 
Here we report the crystal structure of human Nicotinic Acid 
Phosphoribosyltransferase at 2.9 Å resolution in its free state. Our data can 
contribute to shed more light on the catalysis mechanism of this enzyme involved 
in NAD cellular homeostasis and complete the structural bases of the salvage 
pathway enzymes of NAD+ biosynthesis. All these structural data may be used to 











Figure 1. NAD(P)+ biosynthesis in humans. NAD+ biosynthesis initiates from four different 
sources of the pyridine ring, namely QA, Na, Nam and NamR, through three distinct pathways. The 
de novo pathway (blue dotted line) allows NAD biosynthesis starting from QA derived from Trp; 
Na and Nam are processed to NAD+ through the Preiss-Handler pathway enzymes (green dotted 
line), although NamPRTase does not belong to this pathway. The Preiss-Handler independent 
pathway (orange dotted line) is responsible of the pyridine nucleotide synthesis starting from 
NamR. Finally, some of the cellular NAD can be converted into NADP by NAD kinase (EC 
2.7.1.23). QaPRTase, quinolinic acid phosphoribosyltransferase  (EC.2.4.2.19); NaPRTase, 
nicotinic acid phophoribosyltransferase (EC 2.4.2.11); NamPRTase, nicotinamide 
phosphoribosyltransferase (EC 2.4.2.12); NamRKinase, nicotinamide riboside kinase (EC 2.7.1.22); 
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RESULTS AND DISCUSSIONS 
 
 
 Overall Quality of the model  
 
The three-dimensional structure of hNaPRTase has been solved by molecular 
replacement and refined at a resolution of 2.9 Å. The crystal asymmetric unit 
contains a dimer of hNaPRTase and a total of 98 solvent molecules. The two 
protein molecules have been designated as monomers A and B (Figure 2). 
Monomer A contains 503 residues out of 538 and no electron density is present for 
the following regions: first 15 residues at the N-terminus, residues 379-389, 
residues 412-415, and last five residues at the C-terminus. Monomer B contains 
501 residues out of 538 and no density is present for the same regions as in 
monomer A except for the lacking region 408-414 and for the last four C-terminal 
residues. The stereochemistry of the model has been assessed with the program 
PROCHECK (36). 80% of protein residues falls in the most favoured regions of the 
Ramachandran plot with no outliers.  
 
 
Overall structure of human NaPRTase monomer 
 
Human NaPRTase monomer folds into 17 α-helices, 24 β-strands, and the 
connecting loops organized in two domains: an A domain characterized by an 
open-faced sandwich and an irregular α/β barrel, domain B (Figure 3A). The 
Domain A is composed of residues provided by both the N- and C-terminal regions 
(residues 16-127 and 390-534). It consists of 7 α-helices disposed like a shield and 
delimiting the open space where 15 β-strands form 4 antiparallel β-sheets, showing 
a specular two-by-two disposition. Indeed, the seven-stranded fully antiparallel β-
sheet (β1, β3, β5,  β15,  β16, β22 and  β23) and the four-stranded partially 
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antiparallel β-sheet ( β17,  β18,  β21 and  β24) face each other as the other two 
smaller β-sheets do ( β2, β4 and  β19,  β20). The longest helix α5, with 8 turns 
(residues 128-159) connects the two domains and participates in both of them. The 
second domain (residues 160-378) contains a six-stranded α/β core attesting the 
belonging of hNaPRTase to the Type II Phosphoribosyltransferases (PRTases) 
subfamily (Figure 3B). The monomers in the crystal have essentially the same 





Figure 2. The crystal structure of human NaPRTase. The enzyme has a dimeric structure and 
monomers A and B are coloured in orange and green, respectively. Two different orientations of the 
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The dimer of human NaPRTase  
 
hNaPRTase has a predicted molecular weight of 58 kDa and it has been reported to 
show a native molecular mass of about 87,000 Da after gel filtration (37, 33). 
Consistently, our size exclusion data are in accordance with previous analyses (data 
not shown). The native crystal structure of hNaPRTase reveals the presence of an 
intimately associated dimer in the asymmetric unit with 3,000 Å2 of the surface 
area of each monomer buried at the dimer interface. The two monomers are 
arranged head to tail with the N-terminal domain in one monomer contacting the 
α/β barrel in the other monomer (Figure 2). Therefore, the available structural data 
together with the conservation in hNaPRTase of some residues participating in the 
formation of the active site at the dimeric interface in both TaNaPRTase and 
hNMPRTase, as shown by their structural superposition, confirm that the minimal 
functional unit in the hNaPRTase enzyme consists of a dimer. Moreover, it has 
been shown how the major interaction at the dimeric interface in Thermoplasma 
acidophilum NaPRTase is ionic rather than hydrophobic, thus suggesting that the 
oligomeric state could be modulated by different factors such as pH, salt or protein 
concentration influencing these ionic interactions (38). The 3D analysis of the 
surface interaction between hNaPRTase monomers A and B confirmed that the 









Figure 3. Protein fold of hNaPRTase monomer. A. Ribbon representation of the overall structure 
of hNaPRTase monomer. Each monomer consists of two domains: the domain A, characterized by 
an open-faced sandwich, is shown in yellow, while the domain B, formed by an irregular α/β barrel, 
is coloured orange. The two domains are connected by a long α-helix, α5, coloured in grey. B. 
Topology diagram of hNaPRTase. Arrows represent β-strands and cylinders α-helices. Grey β-
strands and α-helices form two structural regions, composed by β9, β10 and α9 and β19, β20 and 
β21 respectively, that appear to be univocally present only in mammal NaPRTases. Long helix α5, 





A open-faced sandwich domain
irregular a/ /b-barrel domain
B
irregular a/ /b-barrel domain
open-faced sandwich domain
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Molecular docking studies 
 
Due to the absence of hNaPRTase substrates co-crystallized within the protein, we 
decided to perform a molecular docking simulation in order to better understand the 
molecular mechanism of the enzyme. The functional dimeric model of hNaPRTase 
was first re-built using the X-ray crystal structure and subsequently refined by 
molecular dynamics simulations. Na, NaMN, Na plus PRPP, and ATP were docked 
in the generated model. 
Na. Docking pose of Na revealed that the nicotinic ring is stabilized in the active 
site by a π-π stacking interaction with Tyr21’. Arg318 results engaged in an ionic 
interaction with the carboxyl group of Na, while Leu170, Gly209 and Leu211 are 
involved in Van der Waals interactions with pyridine ring (Figure 4A). The ligand 
pose is in accord with the Na bound to E. faecalis NaPRT (PDB ID: 2F7F). 
NaMN. The binding mode of nicotinic ring is in accordance with Na binding. A 
hydroxyl group of the sugar moiety is involved in a hydrogen bond with Arg318 
and the phosphate group displays an ionic interaction with Arg171 (Figure 4B). 
Na plus PRPP. The docked pose of Na results quite similar to that previously 
obtained for Na alone. The PRPP docked pose results stabilised by hydrogen bonds 
with Arg318 and Ser214, and by ionic interactions with Arg171 and Lys396’ 
(Figure 4C). Arg171, Arg318 and Ser214 correspond to the same conserved 
residues that in E. faecalis NaPRTase (PDB ID: 2F7F) represent the aminoacids 
involved in the binding of diphosphate. 
ATP. The binding mode is similar to PRPP, since the γ-phosphate group shows 
an ionic interaction with Lys396’ while the β group is involved in hydrogen bonds 
with His213 (backbone amide) and Ser214. The adenine moiety of ATP is involved 
in a π-polar interaction with Arg318 (Figure 4D). 
Molecular docking studies confirm the participation of both monomers of 
hNaPRTase in the formation of the catalytic site. Our observations, based on 
docking analysis on the X-ray structure of hNaPRTase, suggest a new hypothesis 
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on how the enzyme binds its substrates and products that differs from the scenario 
coming from molecular docking studies performed on the structural predicted 





Figure 4. Active site of hNaPRTase at the dimeric interface in complex with different ligands 
as predicted by molecular docking studies. Ribbon representation of the active site formed at the 
dimeric interface, between the α/β barrel domain of monomer A, coloured in orange, and the α1 
helix of monomer B, shown in green. Side chains of residues participating in the coordination of 
ligands (A: Na; B: NaMN; C: Na and PRPP; D: ATP) are represented as thin sticks and their 
identity is indicated, whereas ligands are depicted as green sticks. Hydrogen bonds are shown as 
yellow dotted lines. 
 
 
Comparison with hNMPRTase and hQAPRTase 
 
Despite sharing very limited sequence similarity, hNaPRTase shows a molecular 
architecture that closely resembles those ones firstly described for hNMPRTase 
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common function, consisting in the transfer of the phosphoribosyl group from 
PRPP onto their respective substrates. A DALI search shows that the highest 
similarity is found with hNMPRTase with Z-value of 22.3 (rmsd of 3.8 Å). 
hQAPRTase is the smallest in size among the three, according to the hypothesis 
that is the most ancient (41). Contrarily, hNaPRTase contains 46 and 241 more 
amino acid residues than hNMPRTase and hQAPRTase, respectively. The 
structural superposition of the three enzymes highlights how some of the additional 
residues in hNaPRTase form two structural regions that, from a Blastp research, 
appear to be univocally present only in mammal NaPRTases. The region between 
amino acids 223-264 cointains two β-strands (β9, β10) and one a-helix (α9) that 
extend the borders of the α/β barrel domain and contribute to contact the other 
monomer. Indeed, the side chain of Asp227 is hydrogen bonded to the side chain of 
Arg31 belonging to the other monomer. The second unique region (447-472) of 
hNaPRTase encompasses three β-strands (β19, β20 and β21) that stand at the 








Figure 5. Structural comparison of the three Type II phosphoribosyltransferases involved in 
NAD biosynthesis. Ribbon representations of human quinolic acid phosphoribosyltransferase 
(hQAPRTase), nicotinamide phosphoribosyltransferase (hNMPRTase) and nicotinic acid 
phosphoribosyltransferase (hNaPRTase) are shown separately (left panel) coloured in light blue, 
grey and orange, respectively. The structural superposition of the three enzymes is also represented 
(right panel).  
 
 
Comparison with NaPRTases of other species 
 
The structures of NaPRTase monomers of gram-negative bacteria A. tumefaciens, 
Y. pestis, P. gingivalis, V. cholerae and of the unicellular eukaryote S. cerevisiae 
are very similar. It is quite surprising that the structure of the human NaPRTase is 
more similar to the E. faecalis NaPRTase than to the NaPRTase of the eukaryotic 
S. cerevisiae. It could be hypothesized that this is due to the fact that E. faecalis is a 
commensal bacterium inhabiting the gastrointestinal tract of humans and other 
mammals. Moreover, it has been already established that the small intestine is one 
of the tissue where Na is preferred as source of NAD, so that this can represents an 
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Lack of inhibition by FK866 
 
As previously described in literature, the potent antitumoral agent FK866, bounds 
at the center of the parallel β-sheet in the α/β barrel domain, in a tunnel at the 
dimer interface of hNMPRTase (42). In particular, in hNMPRTase there are two 
small β-strands (region 240-245) that close the circumference outlined by the 
parallel β-sheet at the α/β core; in hNaPRTase, the residues in corresponding 
region (206-211) are oriented closer to the center of the α/β barrel, so determining 
a smaller diameter of the entrance of the tunnel site in hNaPRTase, compared to 
hNMPRTase. This different disposition is due to the presence of an insertion of 10 
residues in hNMPRTase that is not present in hNaPRTase as well as in 
TaNaPRTase (42). Moreover, the orientation of the whole β-sheet forming the 
binding site, compared to that of hNMPRTase, brings the central β-strands β13 and 
β14 to be closer to the center of the barrel of about 4.5 Å compared to those of 
hNMPRTase, with also the loop connecting α14 and β14 sterically preventing the 
binding of the specific FK866 and other antitumoral inhibitors for hNMPRTase 
(Figure 6). The fact that hNaPRTase prevents, in both normal and tumoral cells, 
the formation of Reactive oxygen species (ROS) induced by hNMPRTase 
inhibitors (43), support the envisaged possibility to co-treat with nicotinic acid 
those tumours where hNaPRTase is poorly expressed, in order to increase the 
efficacy of a therapy based on hNMPRTase inhibitors (44). Indeed, the 
administration of nicotinic acid protected non-tumour cells from toxic effects 
resulting from depletion of NAD caused by hNMPRTase inhibition (43). 
Therefore, while strong inhibition of hNMPRTase is the key point for high toxicity 
toward tumour cells, no inhibition should be envisaged for hNaPRTase in order to 
reduce the toxic effect of the anticancer drug.  
  




Figure 6. Structural comparison between hNMPRTase and hNaPRTase at the FK866-
binding site. Human NMPRTase structure in complex with its inhibitor FK866 (PDB ID: 2GVJ) is 
coloured in grey and hNaPRTase is coloured in orange. Structural superposition between these two 
structures poses in evidence the absence, in hNaPRTase, of the tunnel where FK866 binds in 
hNMPRTase. Buried surface areas of hNMPRTase (upper left panel) and hNaPRTase (lower left 
panel) monomers are represented and FK866 is shown as green stick. A ribbon represented close-
up view (right panel) of the superposed secondary structure elements sterically hampering (in 
hNaPRTase) or permitting (in hNMPRTase) the binding of FK866. Light green spheres represent 































NAD+ salvage pathways have a prominent role in cellular NAD metabolism and 
homeostasis. Pyridine nucleotide availability has been shown to be implicated in 
a large number of physiological and pathological conditions. Preiss-Handler 
pathway is responsible for the synthesis of NAD+ starting from Na, and 
NaPRTase represents the first enzyme involved in this ubiquitous salvage route. 
Beyond its role in NAD+ biosynthesis, it was hypothesized that, in humans, 
NaPRTase could be potentially linked to other cellular metabolic pathways. 
Indeed, it has previously been shown that several metabolites related to glucose 
or fatty acid metabolism can influence hNaPRTase activity, thus a pleiotropic 
role for this enzyme could not be excluded (33). Moreover, the substrate of 
NaPRTase, Na, is known to have antidyslipidaemic properties and it has been 
used as a lipid-modifying drug (24). More recently, also the anti-oxidant 
functions of Na have been explored (45-47). Although mechanisms underlying 
the antilypolitic effects of Na are not completely understood, it has been shown 
that Na beneficial properties in protecting against H2O2-citotoxicity depend on 
its intracellular metabolism by NaPRTase (18, 43, 48). Several studies have 
evidenced how hNaPRTase expression levels vary consistently among 
populations and in different pathological conditions (44, 49-51). With respect to 
cancer, evaluation of the structural impact of the numerous hNaPRTase 
mutations found in tumours where the enzyme is poorly expressed, could help in 
predicting the usefulness of a potential co-treatment of these tumours, with Na 
and hNMPRTase inhibitors (49), towards a personalised medical approach. In 
this scenario, our structural and molecular docking results, contribute to a better 
understanding of hNaPRTase molecular mechanism, allowing the study of the 
structure-function relationships.  
  





Enzyme expression and purification 
 
The procedure adopted for the bacterial overexpression and purification of the 
recombinant human NaPRTase has been here reported. The pET32b vector 
(Novagen) plasmid containing the orf for human Nicotinic Acid 
Phosphoribosyltransferase was replicated in Escherichia coli TOP10, sequence-
verified, and transformed into E. coli BL21 (33). In order to have a long term 
storage of the expressing-vector, E.coli BL21 glycerol stocks were prepared by 
adding 50% glycerol to the BL21 cell culture and store them at -80°C. The 
bacterial growth was started by scraping some frozen bacteria then, dissolving them 
into 10 ml 2XTY medium aliquots supplemented with 100 mg/ml Ampicillin. 
Bacteria were grown overnight at 37°C in a slow shake. The cells were then diluted 
(1/40) in the same medium and cultured at 30°C until the optical density at 600 nm 
(OD600) reached 0.6 to 0.8. Expression was induced by addition of isopropyl-D-
thiogalactoside (IPTG) to final concentration of 0.8 mM, and the temperature was 
decreased to 20°C. Cells were harvested by centrifugation after 16 h of induction. 
Induced cells were collected by centrifugation and were resuspended in 1/50 
original volume with 100 mM KH2PO4, pH 8, 300 mM KCl, 10 mM imidazole, 1 
mM β-mercaptoethanol and 250 units of benzonase nuclease. Plasma membranes 
of cells were distrupted by applying a high pressure through the use of the French 
Press twice at 1.5 KBar. Protease inhibitor cocktail was added (100 ml per 40 ml 
extraction Buffer) to the crude extract that was clarified by 1h centrifugation at 
18,000 rpm. The supernatant was purified by a His-tag affinity chromatography 
and a subsequent size-exclusion chromatography as follows. In particular, in the 
first purification step, the solution containing the soluble fraction of human enzyme 
was batch-mixed for 30 min with a Qiagen Ni-NTA resin (0.1 ml per ml extract), 
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previously equilibrated with the buffer, then packed into a chromatographic 
column. The flow-through and the 30mM imidazole buffer wash were discarded. 
The recombinant protein was eluted by 250 and 500 mM imidazole. Protein 
concentration was determined by the Bradford protein assay. Active, SDS-PAGE 
homogeneous fractions were pooled, centrifuged and loaded on a Sephacryl S200 
16/60 column in a FPLC system. Elution Buffer contained 50 mM Hepes/KOH 
buffer, pH 7.5, and 300 mM KCl and the flow rate was 0.2 ml/min. Eluted fractions 
were analysed by SDS-PAGE and used for crystallization trials. All steps were 




Crystallization and Structure Determination  
 
Crystals of hNaPRTase were obtained by means of the vapour diffusion technique 
in sitting drops. 4 ml of a protein solution at a concentration of 15 mg/ml, 
preincubated with 1 mM Acetyl-CoA and 5 mM DTT, were mixed with an equal 
volume of a reservoir solution containing 0.1 M Sodium cacodylate pH 6.5 and 1.7 
M Sodium acetate, and equilibrated against 1.2 ml of the reservoir solution, at 4°C. 
Crystals grew to a maximum dimension of 0.1 x 0.018 x 0.015 mm in about 5 days. 
For X-ray data collection, crystals were quickly equilibrated in a solution 
containing the crystallization buffer and 20% glycerol as the cryo-protectant and 
flash frozen at 100 K under a stream of liquid nitrogen. Data up to 2.9 Å resolution 
were collected at the beamline ID23 EH1 of the European Synchrotron Radiation 
Facility (ESRF, Grenoble, France). Analysis of the diffraction data set collected 
allowed us to assign the crystal to the orthorhombic P212121 space group with cell 
dimensions a = 88.01 Å b = 101.09 Å and c = 125.14 Å containing two molecules 
per asymmetric unit with a corresponding solvent content of 48%. Data were 
processed using the program package XDS (52) and the CCP4 suite of program 
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(53) were used for scaling. The structure determination of hNaPRTase was carried 
out by means of the molecular replacement technique using the coordinates of a 
monomer of Enterococcus faecalis NaPRTase as the search model (Protein Data 
Bank ID code 2F7F). Firstly, an improvement of the quality of the search model 
was carried out by using information contained in the sequence alignment between 
the hNaPRTase and the E. faecalis NaPRTase through the program SCULPTOR 
(54). The new procedure Phenix.mr_rosetta (55), that combines crystallographic 
and structure-modeling algorithms from Phenix and Rosetta, respectively, was used 
to automatically determine the hNaPRTase structure. Phenix.mr_rosetta returned a 
unique molecular replacement solution with an LLG of 44.56 and TFZ=7.4. The 
initial model was subjected to iterative cycles of crystallographic refinement with 
the program PHENIX (56), alternated with manual graphic session for model 
building using the program Coot (57). 5% randomly chosen reflections were 
excluded from refinement of the structure and used for the Free R factor calculation 
(58). The program ARP/wARP (59) was used for adding solvent molecules. When 
the R-factors dropped to a value of R factor and Free R factor of 0.21 and 0.28, 
with ideal geometry at 2.9 Å resolution, we performed an inspection of the electron 
density in the enzyme active site. Data collection and refinement statistics are given 
in Table I.  
  




A molecular dynamics simulation was performed using the GROMACS simulation 
package v.4.5.3 (60) with the standard GROMOS96 force field. The X-ray crystal 
structure of hNaPRTase was energy-minimized in vacuo, using 1000 steps of 
steepest descent in order to remove distorted geometries, and it was embedded in a 
solvent box. The next step was a 2 ns simulation with position restraints to the 
protein, followed by a 500 ps unrestrained simulation. The last 500 ps of the 
simulation were used to compute an average structure for hNaPRTase, which, after 
minimization with 1000 steps of steepest descent, represents the final model. After 
aminoacids’ stereochemistry has been assessed with the program PROCHECK 
(52), the model was used for docking simulations. The ligands tested for docking 
were FK866, Na, NaMN, Na plus PRPP and ATP. Ligand structures were built 
from a SMILES string and were minimized using Omega2 (61). The docking 
simulations were performed using FRED, and using the default settings (62). Each 
ligand-NAPRT complex was subsequent subjected to a molecular structure 
optimization using SZYBKI [(63) SZYBKI 1.7.0] in order to refine the molecular 





The atomic coordinates and structure factors of hNaPRTase have been deposited 





Figures were generated by using the program PyMOL (64).   


































Table I. Data collection and refinement statistics. Values in parentheses are for 
the highest resolution shell. 
  




      2.9 
Observations                      110729 
Unique reflections 25261 (2464) 
R-merge (%)  11.4 (37) 
R-pim (%)  6.1 (20.5) 
Mean (I)/sd (I)                    10.0 (3.7) 
Multiplicity                       4.4 (4.2) 
Completeness (%) 99.7 (99.3) 
Refinement  
 
N° of protein atoms 
 
7576 
N° of solvent molecules 98 
R-work (%) 21.40 
R-free (%)  28.98 
Rmsd Bond lengths (Å) 0.011 
Rmsd Bond angles (°) 1.69 
Mean B-factor main chain (Å2) 36.90 
Mean B-factor side chain   (Å2) 42.67 
Mean B-factor solvent       (Å2) 33.60 
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All NAD+ extracellular precursors and metabolites contribute to NAD+ 
intracellular biosynthesis. However, in order to accomplish this function, cells must 
first take them up. Previous studies have already established that, besides 
nicotinamide and nicotinic acid, only riboside precursors NR and NaR can be 
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transported through the plasma membrane, while mono- and dinucleotide 
precursors should undergo a conversion into their respective nucleosides to sustain 
NAD+ biosynthesis inside cells. Ecto-enzyme CD73 mediates extracellular NMN 
uptake through its 5’-nucleotidase activity by converting it into permeant NR.  
Our studies aim to investigate the metabolic fate of extracellular NMN and NR in 
human hepatocarcinoma cells. Based on the employment of labelled extracellular 
precursors to feed wild type and CD73 knockdown HepG2 cells, we confirm, in a 
direct manner, that extracellular NMN strictly depends on CD73 activity to sustain 
NAD+ biosynthesis. Moreover, our studies strongly suggest that NR is preferred to 
NMN as extracellular precursor in hepatocytes and demonstrate the effectiveness of 
a combined approach, based on the usage of chemical biology tools and LC-MS2 







NAD+ vitamin precursors and NAD+ metabolites are assumed everyday through 
diet. In order to be available for intracellular NAD+ biosynthesis, all these pyridine 
nucleotide building blocks should be first internalised by the cells. Both 
nicotinamide (Nam) and nicotinic acid (Na) are absorbed from the alimentary 
canal, enter the bloodstream for distribution to tissues and finally cells through 
several import mechanisms (1). Nicotinamide riboside (NR), an additional 
salvageable NAD+ precursor entering NAD+ biosynthesis via Nicotinamide 
riboside kinase (Nrks), has been detected in cow milk (2) and it is presumed to be 
translocated from the extracellular to the intracellular compartment by a 
nicotinamide riboside transporter (Nrt), currently unidentified in mammals (3). 
Although nucleoside and nucleobase transport systems have been extensively 
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investigated (4), some other aspects of NAD+ and its nucleotide metabolite uptake 
remain matter of interest and have elicited further investigations. Moreover, the 
import/export mechanisms of either salvageable precursors and NAD+ metabolites 
among cells account also for the signalling functions of NAD+. Indeed, several 
ecto-enzymes hydrolysing extracellular NAD+, ATP and other nucleotides, in 
order to generate signalling molecules or inactivate intercellular signalling via 
extracellular nucleotides, have been described (5-7). These enzymes are expressed 
differently on the plasma membrane of various human cells and tissues (6). Even 
several members of the NAD+-consuming ADP-ribosyltransferase (ART) family 
are expressed on the outer side of the plasma membrane and necessitate of 
extracellular NAD+ to function (8). Extracellular NAD+ has been detected in 
plasma and fluids at low concentrations (9-10) and mounting evidence indicates 
that NAD+ can also be released from cells in a regulated fashion. For example, it 
was demonstrated that NAD+ can cross the plasma membrane through Cx43 
hemichannels to sustain CD38 catalytic activity and second messenger formation in 
fibroblasts (11). Although NAD+ uptake has been postulated in some human cell 
lines (10), other studies showed that nucleosides, but not nucleotides can go 
through the plasma membrane, unless cell-type specific transport systems are 
present (12). In particular, several works have contributed to finally demonstrate 
the dependency of extracellular nicotinamide mononucleotide (NMN) upon CD73 
activity to serve as intracellular NAD+ precursor. CD73 is a 
glycosylphosphatidylinositol (GPI)-anchored protein, known for a long time to be 
responsible of the hydrolysis of nucleoside 5’-monophosphates, mainly AMP, to 
their respective nucleosides and Pi (13). Already in 2006, Belenky and Brenner 
hypothesized the dephosphorylation of extracellular NMN to NR by the surface 
protein CD73, as a step of a potential extracellular NAD+- cycle in vertebrates 
(14). It was only recently, however, that the ability of CD73 to hydrolyse NMN and 
NAD+ through its 5’-nucleotidase activity was demonstrated, thus disclosing its 
possible involvement in systemic NAD metabolism (15). In particular, the enzyme 
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appeared highly active with NMN as substrate, producing NR and Pi. In another 
study, based on the employment of a new detection system (16) to monitor changes 
in NAD content within mitochondria, the fate of NMN as extracellular precursor 
for NAD+ biosynthesis was followed (12). Indeed, NMN uptake was prevented 
when either a competitive substrate for the dephosphorylation by the external 5’-
nucleotidase or plasma membrane nucleoside transporters inhibitors were used, 
thus proving the necessity of its extracellular conversion to its corresponding 
nucleoside NR to serve as intracellular NAD+ precursor (12). Finally, the 
contribute of CD73 in sustaining NAD+ biosynthesis was determined, 
demonstrating that this ecto-enzyme enables the utilisation of extracellular NMN as 
NAD+ precursor by converting it into NR, in FK866-treated tumour cells (17). 
In this study we employed double labelled NMN and NR precursors to feed wild 
type and knockdown CD73 hepatocarcinoma cell lines, and a recently reported LC-
MS2 method (18), to analyse NAD+ metabolites inside and outside fed cells. Our 
results confirm in a direct manner, by means of chemical biology tools, that 
extracellular NMN uptake is dependent on CD73 activity converting it into 
permeant NR. Finally, we show how a combined approach based on labelling 
experiments coupled to LC-MS/MS analysis permits a reliable and comprehensive 









All chemicals and reagents were of analytical grade and were purchased from 
Sigma-Aldrich, unless otherwise stated.  
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Knockdown of CD73  
 
Stable knockdown (KD) CD73 HepG2 cell lines were obtained and provided by 
Dr. Sobol’s group from the Department of Pharmacology and Chemical Biology, 
University of Pittsburgh, USA. Five different viruses expressing shRNA directed 
against CD73 mRNA were designed ad hoc, and wild type (wt) HepG2 cells were 
transfected with them. Moreover, a control KD cell line, transfected with a 
scrambled (scrb) shRNA not interfering with CD73 expression, was obtained. 
 
 
Cell cultures  
 
HepG2 (human hepatocarcinoma) cells, obtained from the American Type Culture 
Collection (ATCC, Manassas, VA), were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) (Life Technologies) supplemented with 10% (v/v) fetal bovine 
serum (FBS) at 37°C in a humified atmosphere with 5% CO2 . KD CD73 HepG2 
cells were grown as stated for wt HepG2 cells with the addition of puromycin (1 





Total RNA was extracted from all KD CD73 HepG2 cell lines using the RNeasy 
Mini Kit (Qiagen). Quality and quantity of RNA were analysed using a NanoDrop 
spectrophotometer (ThermoFisher). cDNA (0.8 µg) was synthesized by using the 
iScript cDNA synthesis Kit (Bio-Rad). PCR primers were designed by using 
Primer 3 software and their sequences were as follows: human CD73, 5’-
CTCCTCTCAATCATGGCGCT-3’ (forward) and 5’-TGGATTCCATTGTTGCG-
TTCA-3’ (reverse); human GAPDH, 5’-GAGTCAACGGATTTGGTGT-3’ 
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(forward) and 5’-GACAAGCTTCCCGTTCTCAG-3’ (reverse); human NRK1, 5’-
GGATGGAAAGCGCAAGACAC-3’ (forward) and 5’-GGAGGCTGATAGAC-
CCTTGTATTAAT-3’ (reverse); human NRK2, 5’-TCCTGACCGTCCCGT-
ATGAA-3’ (forward) and 5’-CCAGGTAGACCACTTCCACAC-3’ (reverse). 
qPCR were performed using the iQ SYBR Green Supermix (Bio-Rad) on the 
CFX96 Real-Time PCR System (Bio-Rad). Statistical analyses of the qPCR were 
obtained by applying the 2-ΔΔCt method, which calculated relative changes in gene 




Western Blot Analyses 
 
70% confluent cells (3x106) were washed twice with cold PBS, collected and 
centrifuged at 1000 rpm for 5 min at 24 °C. Cell pellets were lysed in cold RIPA 
Buffer (Thermo Scientific) (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 
1% sodium deoxycholate, 0.1% SDS). Total, pellet and supernatant fractions 
representing 20% of the total amount of the cells were prepared, resuspended in 
LDS Sample Buffer (Life-Technologies) containing 8% β-mercaptoethanol, loaded 
onto 10% SDS-PAGE (Bio-Rad), then elettrophoretically separated and transferred 
to Immun-Blot PVDF membranes (Bio-Rad). Membranes were blocked with 5% 
non fat dry milk in TBST buffer (1X TBS, 0.1% Tween 20) for 1 h at room 
temperature and incubated with the following antibodies: anti-CD73 (ab124725, 
Abcam Inc., Cambridge, MA) and anti-GAPDH (Abcam). Anti-rabbit IgG, HRP-
linked antibody (Cell Signaling Technology, Danvers, MA) was the secondary 
antibody. Western blots were developed with the ECL-Plus Kit (GE Healtcare), 
according to the manufacturer’s instructions. Band detection and quantitation were 
performed using the ChemiDoc XRS+ System (Bio-Rad) and the Image Lab 
software (Bio-Rad).  
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Labelled precursor synthesis 
 
Synthesis of 18O labelled NR, 18O labelled NMN and deuterated (D),13C double 
labelled NR was performed by Dr. Migaud’s group, School of Pharmacy, Queen’s 
University Belfast, UK.  
 
 
Double labelled NMN Synthesis  
 
Synthesis of D,13C NMN was achieved enzymatically by using the corresponding 
double labelled nucleoside D,13C NR as substrate of human NRK2. Twenty 
enzymatic reactions were set up at the following conditions: 20 mM Hepes sodium 
pH 7.5, 100 mM NaCl, 5 mM MgCl2, 500 µM D,13C NR, 500 µM ATP and 10 µg 
NRK2, in a total volume of 500 µl each at 37°C for 1h. Reaction aliquots were 
stopped by adding 20 mM EDTA and boiling for 2 min at 100°C, then pooled and 
passed through a 3000 MWCO Amicon (Merck Millipore) to eliminate the 26 kDa 
NRK2. Product formation was tested by LC/MS2. The reaction volume was 
fractionated, injected onto a PrincetonSPHER60 SAX 5 µm (250 x 4.6 mm) 
column in a HPLC system (Varian Prostar 210). The flow rate was 1 ml/min and 
the elution conditions were: 8 min at 100% buffer A (10 mM KH2PO4), 30 s at up 
to 100% buffer B (750 mM KH2PO4) and hold at 100% buffer B for 8 min; then the 
gradient returned to 100% buffer A in 30 s and maintained for 6 min. D,13C NMN 
peaks were collected, pooled and loaded on a lyophilizer (VirTis) in order to obtain 
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Label enrichment experiments using single labelled 18O NMN or 18O NR in 
wild type HepG2 cells 
 
Wt HepG2 cells were grown in 150 x 20 mm Petri dishes as specified above. When 
cells reached ≈ 70-80% confluency, complete media was replaced with 
nicotinamide-free media without FBS, and cells were left in these conditions for 24 
h. Subsequently, wt HepG2 cells were supplemented with either 10 µM 18O NR or 
18O NMN. Media and cells were collected before the addition of  the compounds (0 
h), and at the following timepoints: 30 min, 2 h, 4 h, 7 h and 24 h. For each 
timepoint, the corresponding cell pellet was washed with PBS, and media was 
filtered with a sterile 0.2 micron syringe filter, before both being frozen in liquid 
nitrogen and stored at -80°C. All chosen timepoints were tested in duplicate. 




Label enrichment experiments with D,13C NR on scrb and KD3 CD73 HepG2 
cells 
 
The protocol followed to perform label enrichment experiments on KD CD73 
HepG2 cell lines was the same used for wt HepG2 cells; KD3 CD73 and scrb 
HepG2 were supplemented with D,13C NR. Every timepoint was tested once in two 
temporally distinct experiments (biological duplicates). 
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RESULTS AND DISCUSSIONS 
 
 
CD73, NRK1 and NRK2 expression levels in knockdown CD73 HepG2 cell 
lines 
 
By means of qPCR experiments, we determined CD73 mRNA expression levels in 
KD1, KD2, KD3, KD4 and KD5 CD73 HepG2 cells. Our data indicated that KD3 
and KD4 were the most suitable knockdown cell lines to be used for the label 
enrichment experiments with double labelled precursors D,13C NR and D,13C 
NMN. In particular, repeated cDNA synthesis and qPCR experiments on the 
positive control scrb and on KD3 and KD4 HepG2 cell lines, showed that CD73 
expression was 70% depleted in both knockdown mutants (Figure 1). Western blot 
analyses confirmed a lower CD73 expression in KD3 and KD4 HepG2 cell lines 
also at protein level, and the presence of both membrane-bound and cytoplasmic 
CD73 in HepG2 cells, even though CD73 membrane-bound version was 
predominant (data not shown).  
We performed a parallel qPCR experiment to assess which isoform of 
Nicotinamide riboside kinase (NRK) is predominant in HepG2 cells. We found that 
NRK1 is expressed about 400 times more than NRK2 (Table 1); this fact is 
relevant in order to obtain a transient NRK1 knockdown HepG2 cell line to be used 
as a further control in label enrichment experiments. Indeed, by blocking the 
enzymatic activity of the predominant NRK1, cells lose their capacity to use 
extracellular double labelled D,13C NR as precursor for the synthesis of NAD+. 
This transient NRK1 knockdown would be achievable by designing an anti-Nrk1 
shRNA and transforming HepG2 cells with it. Nevertheless, HepG2 cells are 
known in literature to show a low percentage of transformation efficiency (even 
around 10%), but this problem could be overcome through the use of different 
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reverse-transfection protocols and so, transient NRK1 knockdown HepG2 cells is 





Figure 1. CD73 mRNA expression levels in scrb, KD3 and KD4 HepG2 cell line. 
 
 
 HepG2 cells 
Measure 1 Measure 2 Measure 3 Measure 4 Measure 5 Measure 6 Avg M 
Ct GAPDH 18.38 20.03 17.22 19.99 16.87 18.86 18.56 
Ct NRK1 30.32 30.37 28.61 29.08 28.36 28.19 29.16 
Ct NRK2 n.d 37.61 36.86 n.d 38.14 38.12 37.68 
    ΔCt NRK1 = 10.6 ; ΔCt NRK2 = 19.1 
  ΔΔCt = 8.52 
    2- ΔΔCt  = 0.0027 
 
Table 1. qPCR values showing expression levels of GAPDH, NRK1 and NRK2. GAPDH is an 
housekeeping gene in human cells and its expression level is monitored in order to normalise NRK1 
and NRK2 expression level. Cycle threshold number (Ct) represents the number of cycles needed to 
reach a set threshold fluorescent signal level in qPCR experiments. The 2- ΔΔCt method is used and it 
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D,13C NMN Synthesis 
 
For the labelled enrichment experiments on knockdown CD73 HepG2 cells we 
decided to use new double labelled precursors in order to prevent the loosing of the 
label, so obtaining more robust results. Indeed, D,13C NR and NMN carry a label 
on both their nicotinamide and ribosyl moieties (Figure 2). LC-MS2 analysis after 
the enzymatic reaction to synthesize D,13C NMN from D,13C NR, evidenced how 
D,13C NMN production occurred, and 95% of it was double labelled (Figure 3). 
Ion Exchange chromatogram in HPLC system showed that the method used was 
efficient to separate D,13C NMN from other components in the mixture reaction. 
However, chromatogram peak area integration highlighted how D,13C NMN 
synthesis protocol needed to be optimized because not all the D,13C NR was 
converted in the corresponding product (not shown). Unfortunately, the amount of 
D,13C NMN obtained following the reported protocol was not sufficient to perform 




















Figure 3. Fragmentation patterns in the mass spectrum of D,13C NMN. Single labelled peak 
(336.1 m/z) represents the 5% of double labelled peak (337.1).  
 
 
Label enrichment experiments  
 
Both extracellular NMN and NR support intracellular NAD+ biosynthesis (12). 
However, not every cell is capable of converting each NAD+ precursor to NAD+ at 
all times. Indeed, precursors are differentially utilised in a tissue- and cell-specific 
manner (1). Our results from label enrichment experiments on wt HepG2 cells 
show that NR is faster than NMN in entering cells, strongly suggesting that NR is 
preferred to NMN as extracellular precursor in HepG2 cells (Figure 4). When cells 
were threated with 18O NR, all analysed NAD+ metabolites showed a higher 
intracellular percentage of the labelled portion within 24 h, compared to what was 
observed in 18O NMN threated cells. Moreover, the different velocity in NMN and 
NR internalisation and the detection of NR, already after 30 min, in the media of 
18O NMN threated wt HepG2 cells, support the already proved need for NMN to be 
firstly processed to NR in order to serve as intracellular NAD+ biosynthetic 
precursor (12). Indeed, in the last 5 years, different studies have explored the roles 
NRK2 (500 uM 13C, D NR, 500 uM ATP)
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of the human ecto-enzymes, CD38 and CD73, in providing ectocellular precursors 
for NAD+ biosynthesis (12, 15, 17). In particular, these works have already shown 
that extracellular NMN appears to depend upon CD73 or, via Nam, CD38 activities 
to be used as NAD+ precursor. Our label enrichment experiments on knockdown 
CD73 HepG2 cells are aimed to confirm, in a direct manner, the dependency of 
extracellular NMN, as intracellular source of NAD+, upon CD73 activity. As 
expected, our results on KD3 CD73 HepG2 cell line supplemented with D,13C NR, 
showed that NR internalization as well as its contribution in NAD+ biosynthesis 
are not affected by the scarcity of CD73 (data not shown). Label enrichment 
experiments with D,13C NMN on KD CD73 HepG2 cells are currently on-going. 
Our expectation is to see that, when CD73 is expressed at low levels, the entrance 
of NMN into the cells does not occur or occur at a severely reduced rate compared 
to what is observed in wild type cells.  
These experiments also reveal the relationship of the metabolites regardless of the 
precursor (Figure 4). Enrichment of NAD+ is linear with NMN, which is in great 
agreement with the fact that NMN is the direct biosynthetic intermediate to NAD+. 
Nam enrichment occurs at a slower rate than NAD+ and NMN, which suggests two 
important biological relationships: i) NR is not greatly hydrolysed intracellularly to 
Nam and appears to mostly shunt to NAD+ biosynthesis. ii) Most Nam observed in 
the cell is by-product of NAD+-consuming enzymes. NADP enrichment lags 
behind NAD+ and NMN as well, suggesting that the NADP(H) pool is segregated 
from the NAD pool.  
 
  




Figure 4. LC-MS Quantification of NAD(P)+ metabolites after label enrichment experiments 
on wt HepG2 cells. Analysis of pellets (above) and media (below) of cells treated with 18O NR and 
18O NMN are reported on the right and on the left, respectively. The LC-MS2 analysis of cell pellets 
content was based on the measurement over time of the ratio tracer/tracee for each NAD+ 
metabolite, where 180-form constitutes the tracer and 160-form is the tracee. Analyses of the culture 








In literature, other works have already shown that NMN uptake depends upon 
CD73 or, via Nam, CD38 activities. In particular, it has been demonstrated how 
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converted, on the outer side of the plasma membrane, to NR by CD73. In our 
studies we employed double labelled precursors NMN and NR and followed their 
intracellular fate by LC-MS2 analysis. Through this combined approach based on 
chemical biology tools we confirmed, in a direct manner, that extracellular NMN 
sustains NAD+ biosynthesis through CD73-mediated NR formation. Moreover, our 
data strongly suggest that NR on its own is more efficacious than NMN as a 
precursor in HepG2 cells. If potentially extended to other cellular lines, this study 
may also elucidate cellular preferences for distinct extracellular precursors on the 
basis of the tissue or cell type considered. Not of secondary importance, our work 
will also demonstrate the utility of stable labelling experiments coupled to LC-
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In the last 20 years, a breathtaking number of studies have evidenced the 
pleiotropic role of NAD(P) in all organisms. This ubiquitous molecule is a 
fundamental coenzyme as well as a substrate for a plethora of enzymes involved in 
pivotal cellular processes. Indeed, NAD(P) stands at the center of many metabolic 
processes through its function as hydride transporter, and it governs a large number 
of signalling reactions during which it is used as substrate and, therefore, 
consumed. NAD+ biosynthesis is accomplished through different pathways and 
important differences are present among organisms. In humans, NAD+ 
biosynthesis can start from five different precursors, all contributing to replenish 
cellular vital pyridine nucleotide supplies, even though some tissues prefer to use 
one precursor more than the others. Due to NAD(P) essential roles in energy 
metabolism and signalling transduction, its biosynthesis and homeostasis should be 
tightly regulated. In mammals, NAD+ biosynthesis is not a closed, cell-
autonomous system, and intercellular communication determines that NAD 
homeostasis is a systemic and dynamic process influenced by both the 
pathophysiological conditions of the cell and the external environment. 
  
During my PhD, I investigated two aspects involved in NAD homeostasis, 
namely NAD+ biosynthesis and extracellular NAD+ metabolite and precursor 
uptake, both contributing to maintain this fundamental state of balance. NAD+ 
biosynthetic pathways occur intracellularly while the uptake of NAD+ precusors 
takes place on the outer surface of the plasma membrane. Thus, giving a glance at 
what happens either inside and outside cells, our lines of research highlight the 
systemic nature of NAD homeostasis.  
 
My PhD research activity mainly focused on the structural characterisation of 
the recombinant human Nicotinic acid Phosphoribosyltransferase (hNaPRTase). 
hNaPRTase catalyses the first rate-limiting reaction of the three-step Preiss-
Handler pathway, responsible for the synthesis of NAD+ from nicotinic acid (Na). 
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The importance of this NAD+ biosynthetic pathway, as well as the other salvage 
pathways, is underlined by the fact that tryptophan contribution to maintain cellular 
NAD+ levels has been shown to seem negligible in the large majority of human 
organs. Some tissues preferentially use the Preiss-Handler pathway for NAD+ 
biosynthesis, as attested by the fact that Na was found to be more effective than 
nicotinamide (Nam) in increasing NAD+ levels in red blood cells, kidney and 
heart. Indeed, in these tissues hNaPRTase was found to be expressed at high levels. 
Previous studies have already focused on the biochemical characterisation of 
human NaPRTase as well as other NaPRTases from different organisms, 
elucidating some peculiar features of this pivotal enzyme. hNaPRTase is strictly 
specific for Na as substrate and it is not subject to feedback inhibition by NAD+. 
The lack of inhibition by the end product of the pathway together with the 
demonstrated fact that hNaPRTase activity is stimulated by physiological 
concentrations of Pi, suggested that this enzyme could be permanently active in the 
cell. Moreover, it has been shown how, in some organisms, NaPRTase activity can 
be stimulated by ATP through the formation of a phosphoenzyme intermediate, 
thus representing an example for a new energy-coupling mechanism of enzyme 
activation. Nevertheless, biochemical studies could not be supported by a structural 
characterisation of the human enzyme because no crystallographic data have been 
available so far.  
On the basis of a fruitful collaboration with Prof. Orsomando from the 
Department of  Molecular Pathology and Innovative Therapies of the Università 
Politecnica delle Marche (Ancona), who provided us with the cloning vector 
containing the cDNA coding for human  NaPRTase, we overexpressed the 
recombinant protein in Escherichia coli and solved its crystal structure at 2.9 Å in 
its free state by means of molecular replacement. The analysis of hNaPRTase 
crystal structure allowed us to determine its molecular architecture, thus 
contributing to better understand the molecular basis of its functions. hNaPRTase 
consists of two domains: an open-faced sandwich and an irregular α/β barrel, 
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connected by a long α-helix. The α/β core is formed by a six-stranded β-sheet that 
attests hNaPRTase belonging to Type II phosphoribosyltransferase subfamily. The 
analysis of the interactions between the two monomers found in the crystal 
asymmetric unit, together with our size exclusion data, permitted us to determine 
that hNaPRTase minimal functional unit is a dimer. The active site formation 
occurs at the dimeric interface and involves the irregular α/β barrel on one 
monomer, and the N-terminal α1-helix on the other one. In order to identify 
residues involved in ligand coordination and stabilisation in the active site, we 
performed molecular docking studies that confirmed how dimer formation is 
essential for hNaPRTase to function. Moreover, structural comparisons with other 
available NaPRTase structures have evidenced how, surprisingly, the human 
enzyme resembles more to the NaPRTase of Enterococcus faecalis than to the 
enzyme of the eukaryotic Saccaromyces cerevisiae. On the basis of this observation 
and the fact that E. faecalis is a commensal bacterium living in the mammalian 
gastrointestinal tract, we speculated that this similarity could represent an example 
of an adaptive mechanism exploited by the bacterium to survive inside the host. 
Moreover, we compared hNaPRTase structure with the human nicotinamide 
phosphoribosyltransferase (hNMPRTase) and quinolinic acid phosphoribosyl-
transferase (hQAPRTase) structures. Despite sharing very limited sequence 
similarity, these three enzymes showed a resembling molecular architecture, 
consistently with their common function. However, we noticed that some residues 
in hNaPRTase do not superpose with any secondary element in either hNMPRTase 
or hQAPRTase, and form two distinct regions that, from an in silico analysis, 
appeared to be univocally present in mammalian NaPRTases. Finally, the 
superposition between the structures of hNaPRTase and hNMPRTase in complex 
with its potent inhibitor FK866, allowed us to evidence how hNaPRTase does not 
present a tunnel in its active site that constitutes the binding site of the antitumoral 
agent in hNMPRTase. As already shown in Thermoplasma acidophilum 
NaPRTase, this difference is due to the lack in NaPRTase of 10 residues, instead 
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present in hNMPRTase. As a consequence, some secondary structure elements in 
hNaPRTase are disposed in a way that sterically prevents FK866 as well as other 
hNMPRTase inhibitors from binding to hNaPRTase. Given that tumoral cells have 
increased metabolism needs and call for a higher level of NAD+, the blockage of 
its biosynthesis has assumed a therapeutic relevance in cancer treatment. 
hNMPRTase is overexpressed in many tumours and its inhibition by FK866 and 
other inhibitors leads to a severe decrease in NAD+ levels, followed by ATP 
shortage and cell death. However, the redundant nature of NAD+ biosynthesis, 
consisting in several pathways starting from different precursors but ending with 
the formation of the same product, should be considered to evaluate the efficacy of 
cancer treatment with hNMPRTase inhibitors. Unlike hNMPRTase, hNAPRTase 
expression was found to be more varied in tumoral tissues and, therefore, could not 
represent a potential target for chemotherapeutics aiming to decrease NAD+ levels 
in cancer cells. Nevertheless, some tumours have shown high and low or absent 
expression levels for hNMPRTase and hNaPRTase, respectively. For the treatment 
of these tumours, it has been recently disclosed the possibility of increasing the 
therapeutic potential of hNMPRTase inhibitors by co-treating with nicotinic acid. 
In particular, the increment in hNMPRTase inhibitor efficacy mediated by Na co-
treatment consists in diminishing their toxicity for non tumoral tissues. Indeed, 
human NaPRTase is not expressed in these cancers and therefore tumoral cells can 
not synthesize NAD+ starting from Na. On the other hand, hNaPRTase can rescue 
normal cells from NAD+ depletion caused by hNMPRTase inhibition. Moreover, it 
has been proved how hNaPRTase can counteract ROS formation induced in 
tumoral cells by hNMPRTase inhibitors, thus rendering NaPRTase-deficient 
tumours even more suitable for co-treatment with nicotinic acid. Finally, other 
studies have shown that Na possesses potent antioxidant properties and that its 
intracellular metabolism by hNaPRTase is essential for Na to counteract H2O2–
induced cytotoxicity. In this context, we noticed that no inhibition should be 
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envisaged for hNaPRTase in order to reduce the toxic effect of the anticancer 
drugs.  
In summary, our structural studies of human NaPRTase contribute to our 
understanding of its mechanism of action and highlight, through the comparisons 
with other NaPRTases and other enzymes involved in NAD+ biosynthesis, 
structural common features but also hNaPRTase peculiar characteristics. In the 
future, we are planning to obtain point mutated hNaPRTase variants in the residues 
participating in the active site formation in order to validate their importance in 
enzyme activity. Finally, another potential future goal could be to explore the 
molecular basis of the strict hNaPRTase substrate specificity for Na, through a 
protein engineering-based reverse approach aiming to convert hNaPRTase into 
hNMPRTase.  
 
In collaboration with the research group directed by Professor Brenner at the 
Department of Biochemistry of the University of Iowa (USA), we investigated on 
the cellular uptake mechanisms of two extracellular NAD+ metabolites, namely 
nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Previous 
studies have shown the existence of an extracellular NAD+ pool as well as the 
presence of NAD+-consuming enzymes on the outer surface of the plasma 
membrane. Moreover, the major source of NAD+ precursors and metabolites is 
represented by diet and, lately, other studies have underlined the potential 
nutraceutical properties  of NAD+ vitamin precursors, deriving essentially from 
their capacity to boost NAD+ levels. Some of the aspects related to the modalities 
used by the cells to take up extracellular NAD+ metabolites remain unclear. For 
example, it has been shown how extracellular NR can sustain intracellular NAD+ 
biosynthesis without undergoing any enzymatic conversion in the extracellular 
compartment, but nowadays the molecular identity of its transporter through the 
plasma membrane is still unknown in mammals. Several works have contributed to 
finally demonstrate the dependency of extracellular NMN upon the enzymatic 
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activity of the surface protein CD73 to serve as intracellular NAD+ precursor. 
CD73 is a cell surface enzyme, linked to the plasma membrane by a 
glycosylphosphatidylinositol (GPI) anchor in its C-terminal domain, and catalyses 
the dephosphorylation of extracellular purine and pyrimidine ribo- and 
deoxyribonucleoside monophosphates to their corresponding membrane permeable 
nucleosides. In a previous study from our laboratory, it was reported that CD73 is 
also capable of processing both NAD+ and NMN through its 5’-nucleotidase 
activity. In particular, the enzyme appeared highly active with respect to NMN as a 
substrate, producing NR and Pi. Recently, Grozio and collaborators finally 
demonstrated the role of CD73 in sustaining intracellular NAD+ biosynthesis by 
converting extracellular NMN into NR, in FK866-treated tumour cells.  
In this context, we set ourselves a double objective: to confirm in a direct 
manner the close dependence of extracellular NMN upon CD73, and to explore 
hepatocytes preferences in terms of extracellular precursors for intracellular NAD+ 
biosynthesis. To address these purposes, we used CD73 knockdown 
hepatocarcinoma cell lines (HepG2), provided by Dr. Sobol’s group of the 
University of Pittsburgh (USA), and chemical biology tools provided by Dr. 
Migaud’s group of the Queen’s University Belfast (UK). First, we selected, from  a 
panel of CD73 knockdown HepG2 cell lines, those ones showing the lowest CD73 
expression, at both the transcriptional and translational levels. Indeed, we grew 
wild type and CD73 knockdown HepG2 cells in the absence of nicotinamide for 24 
h, and then fed them with either singly or doubly labelled NMN and NR, 
respectively. We finally analysed the metabolic fate of the labelled extracellular 
precursors by LC-MS2, following intracellular NAD+ metabolome variations over 
time. Our results from label enrichment experiments on wild type cells showed that 
NR is faster than NMN in entering cells, strongly suggesting that NR is preferred to 
NMN as extracellular precursor in human hepatocytes. Moreover, the detection of 
NR in the media of cells treated with labelled NMN, is in accordance with the 
necessity for NMN to be dephosphorylated by CD73 before being internalised by 
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the cell. As expected, label enrichment experiments on the selected CD73 
knockdown cells supplemented with double labelled NR showed that its uptake is 
not affected by CD73 low levels of expression. Label experiments on CD73 
knockdown cells with double labelled NMN and the optimization of its production 
protocol via NRK, are ongoing. Nevertheless, we are tempted to say that our last 
results will confirm the dependency of NMN upon CD73, as previously reported in 
literature. In the near future, we aim to obtain a transient NRK1 knockdown HepG2 
cell line to be used in label enrichment experiments. We have already determined 
that NRK1 is the most prominent nicotinamide riboside kinase isoform to be 
expressed in hepatocarcinoma cells. Therefore, when NRK1 expression is 
impaired, we expect to see that NAD+ rescue will be prevented for both double 
labelled NMN and NR. Thus, the employment of this transient knockdown cell line 
could offer a further direct evidence of how usage of extracellular NMN, as a 
precursor for intracellular NAD+ biosynthesis, can occur only after its CD73-
mediated dephosphorylation to NR. Our studies represent also a demonstration of 
the effectiveness of a combined approach, based on the usage of chemical biology 
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“Non costa nulla e produce molto, arricchisce chi lo riceve 
senza impoverire chi lo dona. 
Non dura che un istante, ma nel ricordo può essere eterno. 
E’ il segno indelebile di un’amicizia profonda. 
Nessuno è così ricco da poterne fare a meno 
e nessuno così povero da non meritarlo. 
Un sorriso dà riposo alla stanchezza e allo scoraggiamento; 
rinnova il coraggio, nella tristezza è consolazione. 
Un sorriso è un bene che ha valore nell’istante in cui si dona. 
Se incontrerai chi il sorriso a te non dona, sii generoso e dà il tuo, 
perché nessuno ha tanto bisogno di sorriso 
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